Q1: What is robotic cancer surgery and how is it different from open surgery?

Ans: Robotic cancer surgery uses a surgeon-controlled robotic system to perform complex operations through small keyhole incisions — typically 4 to 6 ports, each just 8 to 12mm wide. Unlike conventional open surgery, which requires a large incision and significant disruption of surrounding muscles and tissues, robotic surgery is minimally invasive while achieving equivalent or superior cancer removal. The surgeon operates from a console, viewing a magnified high-definition 3D image of the surgical field and translating hand movements into precise robotic instrument actions inside the body. The result is significantly less blood loss, lower infection risk, shorter hospital stay, less post-operative pain, and faster return to normal life — without compromising the oncological principles of complete cancer removal.

Q2: How does the da Vinci robotic surgery system work?

Ans: The da Vinci robotic system consists of three components: a surgeon console, a patient-side cart with robotic arms, and a vision tower. The surgeon sits at the console and controls robotic arms that hold tiny wristed instruments and a high-definition 3D camera inserted through small ports in the patient's body. Every movement of the surgeon's hands — including fine tremor filtering — is precisely translated in real time into the patient's body with a degree of dexterity impossible by the human hand alone. The 10x magnified, three-dimensional view allows the surgeon to operate in confined anatomical spaces with a level of precision that is particularly valuable during cancer resections near critical nerves and blood vessels.

Q3: Is robotic surgery done by a robot or by a doctor?

Ans: Robotic surgery is performed entirely by a trained surgeon — the robot does not operate independently at any point. The robotic system is a sophisticated tool that amplifies and refines the surgeon's own hand movements; it has no autonomous capability. The surgical oncologist controls every step of the procedure from the console, making all operative decisions in real time. This distinction is important: the quality of a robotic cancer surgery is entirely dependent on the surgeon's oncological training, experience, and judgement. At Sahyadri Manipal Hospital, Pune, all robotic cancer surgeries are performed by Dr. Vinod Gore — Department Head Surgical Oncology, Tata Memorial-trained, with FARIS Edinburgh fellowship and nearly 30 years of surgical experience.

Q4: Is robotic surgery safe for cancer patients in India?

Ans: Yes. Robotic cancer surgery is a globally established, well-validated surgical approach and is safely practised across major hospitals in India. It has been performed for over two decades worldwide, with extensive published data confirming its safety and oncological equivalence to open surgery across multiple cancer types. In India, robotic surgical systems are approved by the Central Drugs Standard Control Organisation (CDSCO) and are used at leading cancer centres including Tata Memorial Hospital, AIIMS, Apollo, and Sahyadri Manipal Hospital, Pune. Dr. Vinod Gore, Department Head Surgical Oncology and FARIS Edinburgh, leads a dedicated robotic oncosurgery programme at Sahyadri Manipal Hospital — recognised as a Robotic Surgery Centre of Excellence — ensuring the highest standards of patient safety.

Q5: What are the main benefits of robotic surgery over laparoscopic surgery?

Ans: While both robotic and laparoscopic surgery are minimally invasive, robotic surgery offers several important technical advantages. The robotic system provides a fully immersive, magnified three-dimensional view compared to the flat 2D view of standard laparoscopy. Robotic instruments have seven degrees of freedom — including a wristed motion that mimics the human wrist — enabling complex manoeuvres inside the body that are simply not possible with rigid laparoscopic instruments. The system also filters out the natural tremor in the surgeon's hands, improving precision. These advantages are particularly significant during complex cancer resections in tight anatomical spaces such as the deep pelvis, the mediastinum, and the hepatopancreatic region where precision is paramount.

Q6: What are the risks and complications of robotic cancer surgery?

Ans: As with any major surgery, robotic cancer surgery carries risks — including bleeding, wound or port-site infection, injury to nearby organs such as the ureter, bowel, or blood vessels, deep vein thrombosis, and anaesthetic complications. These risks are similar in nature to open surgery, though their frequency and severity are generally lower with the robotic approach due to better visualisation and precision. Robotic-specific issues such as instrument failure are extremely rare. The overall complication rate is significantly influenced by the surgeon's experience and the volume of procedures performed at the centre. At Sahyadri Manipal Hospital, Pune, a systematic approach to pre-operative risk assessment, operative technique, and post-operative care minimises complications across all robotic cancer surgery procedures.

Q7: How long does a typical robotic cancer surgery take?

Ans: Operating time for robotic cancer surgery varies considerably depending on the type and complexity of the procedure. A robotic radical prostatectomy typically takes 2 to 4 hours; robotic low anterior resection for rectal cancer 3 to 5 hours; robotic gastrectomy 3 to 5 hours; and robotic Whipple's procedure (pancreaticoduodenectomy) 5 to 8 hours for complex cases. Robotic thoracic lobectomy for lung cancer typically takes 2 to 4 hours. In general, robotic procedures may take slightly longer than their open equivalents — particularly in a surgeon's earlier cases — but this time investment is well justified by the significantly reduced recovery time and post-operative complications that benefit the patient. Your surgeon will advise specifically based on your procedure.

Q8: How small are the incisions in robotic surgery?

Ans: Robotic surgery uses 4 to 6 small circular port incisions, each measuring between 8 and 12mm in diameter — roughly the size of a fingernail. These ports are used to insert the robotic instruments and the camera into the body. In some procedures, a small access incision of 3 to 5cm may also be needed to retrieve the surgical specimen. Compared to a conventional open surgical incision — which can measure 20 to 30cm or more for major abdominal and thoracic procedures — the difference in wound size, tissue disruption, and post-operative pain is dramatic. Smaller incisions translate directly into faster wound healing, lower infection risk, and improved cosmetic outcomes, which are particularly meaningful for patients recovering from cancer surgery.

Q9: Will I have visible scars after robotic surgery?

Ans: Scars from robotic surgery are minimal compared to open surgery. Most patients are left with 4 to 6 small circular marks from the port sites, typically measuring 8 to 12mm each, plus occasionally a slightly larger incision used to remove the specimen. These marks fade significantly over 6 to 12 months and are generally much less conspicuous than the long linear scars of open surgery. For certain robotic procedures — such as robotic thyroidectomy performed via the transaxillary or retroauricular approach — there is no scar on the neck at all. Similarly, robotic mastectomy performed through an axillary port leaves no scar on the breast. For patients with significant concerns about scarring or those in visible-profession roles, robotic surgery can offer meaningful cosmetic advantages.

Q10: How much blood loss occurs during robotic surgery compared to open surgery?

Ans: Blood loss during robotic cancer surgery is typically 60 to 80 percent less than during equivalent open procedures. This is one of the most consistent and clinically significant advantages of the robotic approach. The magnified three-dimensional view allows the surgeon to identify and carefully seal small blood vessels before dividing them, greatly reducing intraoperative bleeding. Less blood loss means fewer patients require blood transfusions, which carry their own risks. It also means a more stable operative field, faster surgery, and a smoother post-operative recovery. For patients with anaemia or those who decline blood products on religious or personal grounds, the robotic approach offers an important advantage over conventional open cancer surgery.

Q11: Is robotic surgery more painful than laparoscopic surgery?

Ans: Robotic surgery and laparoscopic surgery are broadly comparable in terms of post-operative pain, and both are significantly less painful than open surgery. Because both approaches avoid large incisions and minimise disruption to the surrounding muscles and chest or abdominal wall, patients experience substantially less pain in the days and weeks following the procedure. Most robotic surgery patients require only oral pain medication within 48 to 72 hours of the operation, and the majority are walking comfortably within 24 hours. The reduced pain burden after robotic surgery has direct practical benefits — it allows earlier mobilisation, reduces the risk of post-operative chest complications, and contributes to a faster overall recovery compared to open surgical approaches.

Q12: How long is the hospital stay after robotic cancer surgery?

Ans: Hospital stay after robotic cancer surgery is typically 3 to 7 days for most procedures — significantly shorter than the 7 to 14 days common after equivalent open operations. The exact duration depends on the type of surgery, the patient's overall health, and any post-operative requirements. For example, after robotic prostatectomy, patients are generally discharged within 2 to 3 days; after robotic colectomy, 3 to 5 days; after robotic esophagectomy, 7 to 10 days. The shorter hospital stay is not merely a convenience — it reduces the risk of hospital-acquired infections, minimises disruption to the patient's daily life, and lowers the overall financial burden of the surgical admission. Patients receive detailed discharge instructions and follow-up plans from the Sahyadri Manipal team.

Q13: When can I return to work after robotic surgery?

Ans: Return to work after robotic cancer surgery is significantly faster than after open surgery, though the exact timeline depends on the type of procedure and the nature of the patient's work. Most patients with desk-based or office jobs can return to light work within 3 to 4 weeks of robotic surgery. Those with physically demanding roles — involving lifting, manual labour, or prolonged standing — generally require 6 to 8 weeks before returning to full duty. This compares favourably to open surgery, which typically requires 8 to 12 weeks before patients with physical roles can safely return to work. Your surgeon at Sahyadri Manipal Hospital will provide specific, individualised return-to-work guidance based on your procedure, recovery progress, and professional requirements.

Q14: Can robotic surgery cure cancer completely?

Ans: Robotic surgery can achieve complete cancer removal — technically described as an R0 resection, meaning no cancer cells at the cut margins — which is equivalent to what open surgery achieves for the same procedure. Whether surgery results in a cure depends on multiple factors beyond the surgical technique: the cancer's stage at the time of diagnosis, the tumour's biological behaviour, whether lymph nodes are involved, and whether the cancer has spread to distant sites. Robotic surgery is one important component of a comprehensive cancer treatment plan that often includes chemotherapy, radiation therapy, hormone therapy, or targeted therapy depending on the cancer type and stage. The oncological decision-making around your treatment plan remains entirely the same regardless of whether surgery is performed robotically or through open technique.

Q15: Is robotic surgery suitable for elderly patients above 70?

Ans: Robotic surgery is frequently preferred for elderly patients precisely because it is less physically traumatic than open surgery. The smaller incisions, reduced blood loss, lower risk of wound complications, and faster recovery make the robotic approach particularly well-suited for older patients who may have less physiological reserve to cope with the demands of a large open operation and its prolonged recovery. Fitness for surgery is assessed individually based on cardiovascular function, lung capacity, kidney function, nutritional status, and other relevant medical conditions — not on age alone. Many patients in their 70s and 80s safely undergo complex robotic cancer operations at Sahyadri Manipal Hospital, Pune, with excellent outcomes under the care of Dr. Vinod Gore's experienced surgical oncology team.

Q16: Can diabetic and hypertensive patients undergo robotic cancer surgery?

Ans: Yes. Patients with diabetes, hypertension, or other common medical conditions can safely undergo robotic cancer surgery, provided these conditions are appropriately optimised before the operation. Pre-operative preparation involves achieving good blood sugar control — ideally HbA1c below 8 percent — and ensuring blood pressure is well-managed. An experienced anaesthesia team monitors metabolic parameters closely throughout the procedure. The robotic approach itself is advantageous for patients with diabetes, because smaller incisions heal more reliably than the large open wounds which carry a significantly higher risk of wound breakdown and infection in diabetic patients. Dr. Vinod Gore's team at Sahyadri Manipal Hospital conducts thorough pre-operative assessments for all patients to ensure surgery is safe and well-planned.

Q17: What anaesthesia is used during robotic surgery?

Ans: General anaesthesia is used for all robotic cancer surgery procedures. The patient is completely asleep and pain-free throughout the operation. A dedicated team of experienced anaesthesiologists at Sahyadri Manipal Hospital monitors all vital parameters — blood pressure, heart rate, oxygen saturation, end-tidal CO2, depth of anaesthesia, and fluid balance — continuously during the procedure. Robotic surgery also requires the patient to be positioned in specific postures — such as steep Trendelenburg (head-down tilt) for pelvic robotic procedures — and the anaesthesia team manages the physiological effects of these positions and of the CO2 gas used to inflate the abdomen. Modern short-acting anaesthetic agents allow faster emergence from anaesthesia and significantly less post-operative nausea compared to older techniques, improving patient comfort after major cancer surgery.

Q18: Can the robot fail or malfunction during surgery?

Ans: Robotic system technical faults are extremely rare. Modern da Vinci robotic platforms incorporate multiple redundant safety mechanisms, continuous self-diagnostic monitoring, and automatic error detection. The system is designed to stop safely and alert the surgical team if any component behaves outside expected parameters. In the unlikely event of a technical issue that cannot be immediately resolved, the surgeon converts the procedure to laparoscopic or open surgery — a protocol that is routinely rehearsed and can be executed safely and quickly. Conversion is not a failure; it is a pre-planned safety pathway. Dr. Vinod Gore and his team at Sahyadri Manipal Hospital are fully trained in managing such eventualities, and the robotic programme conducts regular safety drills and equipment maintenance checks to ensure consistent reliability.

Q19: What happens if there is a complication mid-surgery — can it be converted to open surgery?

Ans: Yes. Every robotic procedure can be safely and rapidly converted to open surgery if needed during the operation. This is a standard, pre-planned safety protocol — not an emergency measure. Conversion may be required for unexpected bleeding, difficult anatomy, equipment issues, or any situation where the surgeon's clinical judgement indicates open surgery will better serve the patient's safety and oncological interests. Conversion to open surgery is not a surgical failure; it reflects the surgeon's good clinical judgement and priority for patient safety over completing a minimally invasive approach at all costs. At Sahyadri Manipal Hospital, Pune, the operating theatre is always prepared to transition to open surgery at any point during a robotic procedure, and all team members are trained in this pathway.

Q20: Is robotic surgery FDA-approved and approved by Indian regulatory bodies?

Ans: Yes. The da Vinci robotic surgical system, manufactured by Intuitive Surgical, is approved by the United States FDA for use in multiple surgical specialities including urology, gynaecology, general surgery, thoracic surgery, and head and neck surgery — encompassing the full range of cancer operations. In India, robotic surgical systems are approved by the Central Drugs Standard Control Organisation (CDSCO), which is the Indian equivalent of the FDA. Sahyadri Manipal Hospital, Pune holds NABH accreditation and its robotic surgery programme operates in full compliance with all applicable Indian and international regulatory standards. The hospital's robotic programme has also been designated a Centre of Excellence by the Robotic Surgeons Association, reflecting adherence to the highest standards of training, safety, and clinical outcomes.

Q21: How many robotic cancer surgeries are performed in India every year?

Ans: The exact national figure is not centrally published, but India performs several thousand robotic cancer surgeries annually across major centres in cities including Mumbai, Delhi, Bangalore, Chennai, Hyderabad, Pune, and others. The volume is growing rapidly year on year as more hospitals invest in robotic platforms, more surgeons receive formal training through programmes such as the FARIS fellowship and RSA India certification, and as patient awareness of the benefits of robotic surgery increases. India is now among the leading countries in Asia for the volume and diversity of robotic oncosurgery performed. Dr. Vinod Gore's robotic programme at Sahyadri Manipal Hospital, Pune has been operational since the department's early years and has accumulated experience across all major organ systems.

Q22: What is the success rate of robotic cancer surgery in India?

Ans: Success rates for robotic cancer surgery in India, at experienced centres, are comparable to internationally published benchmarks from the USA, Europe, Japan, and South Korea. Cancer control outcomes — including R0 resection rates, lymph node yield, and long-term survival — are equivalent to open surgery for colorectal, gastric, prostate, kidney, endometrial, and other cancers. Complication rates and post-operative recovery metrics — including blood loss, transfusion requirements, hospital stay, and readmission rates — are generally better with robotic surgery than with open surgery. At Sahyadri Manipal Hospital, Pune, Dr. Vinod Gore's robotic oncosurgery programme — a recognised Centre of Excellence — maintains outcomes that meet or exceed national benchmarks. Your surgeon will discuss specific expected outcomes for your individual cancer type and stage.

Q23: Robotic surgery kya hota hai aur kaise hoti hai?

Ans: Robotic surgery ek aisi modern surgical technique hai jisme surgeon ek computer console se robotic haath control karta hai. Yeh robotic haath patient ke pet ya seene mein chhote chhedon — sirf 8 se 12mm ke — ke zariye daale jaate hain. Surgeon ko ek 3D, high-definition screen pe andar ka poora nazar aata hai jo bahut zyada zoom hota hai. Koi bada chiira nahi lagta, isliye dard bahut kam hota hai, khoon kam nikalta hai, aur patient jaldi theek hota hai. Sahyadri Manipal Hospital, Pune mein Dr. Vinod Gore — Department Head, Surgical Oncology aur FARIS Edinburgh holder — sab bade organ systems ke cancer ki robotic surgery karte hain. Yeh ek recognised Centre of Excellence hai.

Q24: Is robotic surgery better than chemotherapy for cancer treatment?

Ans: Robotic surgery and chemotherapy are fundamentally different treatments that address different aspects of cancer — they are not alternatives to each other, and comparing them directly is not clinically meaningful. Surgery physically removes the primary tumour and its draining lymph nodes; chemotherapy targets cancer cells that may have spread through the bloodstream to other parts of the body. Many cancers require both treatments in sequence — surgery first, followed by adjuvant chemotherapy, or chemotherapy first (neoadjuvant) to shrink the tumour before surgical removal. The appropriate combination and sequence of treatments depends entirely on your cancer type, stage, and biology, and should be planned by an experienced surgical oncologist working in coordination with a medical oncologist and radiation oncologist.

Q25: Why should I choose robotic surgery over traditional surgery for my cancer?

Ans: Robotic surgery offers a compelling combination of oncological precision and patient-friendly recovery. For patients diagnosed with cancer, the decision between robotic and open surgery should be based on the specific cancer type, stage, anatomical location, and the surgeon's expertise. Robotic surgery is particularly advantageous for cancers in confined anatomical spaces — such as low rectal cancer in the pelvis, prostate cancer, thoracic tumours, and complex GI cancers — where three-dimensional magnification and wristed instrument movement provide a meaningful technical advantage over open technique. The benefits of less pain, fewer wound complications, shorter hospital stay, and faster return to normal life and employment are real and well-documented. At Sahyadri Manipal Hospital, Pune, Dr. Vinod Gore will guide you honestly on whether robotic surgery is the right approach for your individual case.

Q26: What is a robotic Whipple's procedure (pancreaticoduodenectomy)?

Ans: The Whipple's procedure — formally called pancreaticoduodenectomy — is one of the most complex operations in abdominal surgery. It involves removing the head of the pancreas, the duodenum, the gallbladder, the common bile duct, and sometimes part of the stomach, for cancers arising in the pancreatic head, the ampulla of Vater, the distal bile duct, or the duodenum. The robotic Whipple uses 5 to 6 small port incisions instead of a large abdominal cut and offers the significant advantage of a magnified three-dimensional view during the intricate pancreatic, biliary, and gastric reconstruction steps. This precision reduces the risk of anastomotic leak — the most feared complication — and results in less blood loss and faster post-operative recovery compared to open Whipple surgery.

Q27: Is robotic Whipple surgery available in Pune?

Ans: Yes. Robotic Whipple surgery — robotic pancreaticoduodenectomy — is available at Sahyadri Manipal Hospital, Pune. Dr. Vinod Gore, Department Head Surgical Oncology, is a Tata Memorial Hospital-trained surgical oncologist with FARIS Edinburgh fellowship and nearly 30 years of experience performing complex hepatopancreatic and biliary oncosurgery. His robotic programme at Sahyadri Manipal Hospital is designated a Robotic Surgery Centre of Excellence. Patients from Pune, Maharashtra, and across India who require robotic Whipple surgery for pancreatic head cancer, ampullary cancer, cholangiocarcinoma, or duodenal cancer can seek consultation at Silver Leaf Clinic, Hadapsar, or directly at Sahyadri Manipal Hospital. Teleconsultation is available for outstation patients.

Q28: How is a robotic Whipple different from an open Whipple procedure?

Ans: An open Whipple procedure requires a large upper abdominal incision — typically 20 to 25cm — giving the surgeon direct access to the pancreatic head and surrounding structures. This large incision results in significant post-operative pain, a higher risk of wound complications, and a recovery period of 6 to 10 weeks at home. The robotic Whipple, by contrast, uses 5 to 6 small port incisions and provides a magnified, three-dimensional view of the operative field — allowing the surgeon to perform the complex dissection around the superior mesenteric vessels and the three anastomoses (pancreatic, biliary, and gastric) with greater precision. Blood loss is substantially lower with robotic technique, and hospital stay is typically shorter, allowing patients to begin adjuvant chemotherapy sooner after surgery.

Q29: What is the success rate of robotic Whipple surgery for pancreatic cancer?

Ans: In experienced centres, robotic Whipple surgery achieves equivalent cancer control to open Whipple surgery. The critical oncological measure — the R0 resection rate, meaning complete removal with clear surgical margins — is comparable between robotic and open approaches when performed by experienced HPB surgeons. Survival outcomes for pancreatic cancer after robotic Whipple are equivalent to open surgery. The robotic approach does confer measurable advantages in blood loss, transfusion requirements, and wound complications. Importantly, adequate lymph node harvest — a key quality metric for pancreatic cancer surgery — is well achieved robotically. Pancreatic cancer outcomes are also significantly influenced by tumour biology and stage at diagnosis, both of which are independent of the surgical approach used.

Q30: How long is recovery after robotic Whipple surgery?

Ans: Recovery after robotic Whipple surgery involves an in-hospital stay of approximately 7 to 10 days — compared to 10 to 14 days after open Whipple. Patients typically spend the first 24 to 48 hours in the ICU or high-dependency unit before being transferred to the ward. Oral diet is resumed progressively — starting with clear fluids and advancing to soft and then normal diet over the first 2 to 4 weeks at home. Full recovery — including return to normal energy levels, resumption of driving, and return to work — typically takes 4 to 6 weeks for robotic Whipple compared to 8 to 12 weeks for open surgery. Pancreatic enzyme supplementation and a detailed dietary plan are essential components of the recovery programme and are provided by Dr. Gore's team.

Q31: What is the cost of robotic Whipple surgery in India?

Ans: Robotic Whipple surgery in India typically costs between Rs 4.5 lakhs and Rs 8 lakhs, depending on the hospital, the city, the duration of surgery, the length of ICU stay, and any post-operative complications that may extend the admission. This figure covers the surgical procedure, anaesthesia, robotic consumables (single-use instruments), ICU monitoring, ward accommodation, nursing care, and standard medications. It does not typically include pre-operative investigations, pathology, post-operative chemotherapy, or outpatient follow-up. At Sahyadri Manipal Hospital, Pune, the hospital's billing department provides a detailed cost estimate before admission. Cashless insurance is accepted with prior TPA pre-authorisation. MJPJAY and Ayushman Bharat coverage is available for eligible patients.

Q32: Is robotic surgery suitable for advanced pancreatic cancer?

Ans: Robotic surgery for pancreatic cancer is best suited for resectable tumours — typically Stage I and early Stage II disease where the tumour has not grown into the superior mesenteric artery, celiac axis, or other major adjacent vessels. For locally advanced pancreatic cancer (Stage III), the standard approach is neoadjuvant chemotherapy — usually FOLFIRINOX or gemcitabine-nab-paclitaxel — followed by restaging imaging to determine whether surgical resection has become feasible. Borderline resectable tumours may also be considered for surgery after chemotherapy in selected cases. For Stage IV metastatic pancreatic cancer, systemic chemotherapy is the primary treatment; surgery is not the standard approach. Your surgical oncologist will review all imaging carefully before advising on the surgical plan.

Q33: What is a robotic esophagectomy and when is it recommended?

Ans: Robotic esophagectomy removes the oesophagus — the food pipe — for oesophageal cancer, most commonly squamous cell carcinoma or adenocarcinoma. It is typically recommended after a course of neoadjuvant chemoradiation, which shrinks the tumour before surgical removal. The operation reconnects the stomach (fashioned into a gastric conduit) with the remaining upper oesophagus or pharynx in the chest or neck. The robotic approach offers several advantages over conventional open esophagectomy: less chest wall and abdominal wall trauma, superior visualisation during thoracic lymph node dissection, reduced pulmonary complications post-operatively, and lower blood loss. Dr. Vinod Gore has a dedicated research interest in thoracic oncology, having completed a Research Fellowship in Thoracic Oncology at Tata Memorial Hospital, Mumbai.

Q34: Can robotic surgery treat esophageal cancer at all stages?

Ans: Robotic esophagectomy is appropriate for Stages I through III oesophageal cancer following a complete staging workup — including CT chest-abdomen-pelvis, PET-CT, endoscopic ultrasound, and bronchoscopy where indicated. Stage I cancers confined to the mucosa or submucosa may sometimes be treated endoscopically without open surgery; Stage II and III cancers are typically treated with neoadjuvant chemoradiation followed by robotic or open esophagectomy. Stage IV metastatic oesophageal cancer is generally not treated surgically — palliative systemic chemotherapy, with or without stenting for dysphagia, is the standard of care. Exact staging and treatment decisions are made by the treating oncology team based on a comprehensive review of pathology, imaging, performance status, and patient preference.

Q35: How long is the ICU stay after robotic esophagectomy?

Ans: Patients undergoing robotic esophagectomy typically spend 1 to 3 days in the intensive care unit (ICU) following surgery, compared to 3 to 5 days after conventional open esophagectomy. ICU care involves monitoring of the chest drain output, respiratory function, heart rhythm, fluid balance, and the integrity of the gastric conduit. After ICU discharge, the patient is transferred to the surgical ward for further recovery, typically remaining in hospital for a total of 7 to 12 days. Pulmonary physiotherapy — deep breathing exercises, incentive spirometry, and early mobilisation — are central to post-esophagectomy recovery and significantly reduce the risk of the most common serious complication, which is pneumonia. Swallowing assessment and graded diet reintroduction are supervised by the team before discharge.

Q36: What is a robotic gastrectomy and when is it done for stomach cancer?

Ans: Robotic gastrectomy removes all or part of the stomach for gastric (stomach) cancer. Distal gastrectomy removes the lower two-thirds of the stomach with anastomosis to the jejunum; total gastrectomy removes the entire stomach when tumour location or extent requires it. Robotic gastrectomy is indicated for resectable Stage I, II, and selected Stage III gastric cancers. A key quality benchmark for gastric cancer surgery is the D2 lymphadenectomy — removal of the second tier of gastric lymph nodes — which is a technically demanding dissection that is facilitated by the superior visualisation and precision of the robotic system. Robotic D2 gastrectomy achieves equivalent nodal clearance to open surgery with less blood loss, lower wound complication rates, and faster patient recovery.

Q37: Robotic total gastrectomy vs distal gastrectomy — which is right for me?

Ans: The choice between total and distal robotic gastrectomy is determined entirely by the location and extent of the stomach tumour, not by patient preference or convenience. Tumours of the antrum, pylorus, or lower body of the stomach are typically managed with distal gastrectomy, which preserves the upper stomach and offers better nutritional outcomes long term. Tumours of the upper stomach (fundus, cardia, gastro-oesophageal junction) or diffuse gastric cancers (such as linitis plastica) generally require total gastrectomy with a Roux-en-Y reconstruction. Your surgical oncologist will review your endoscopy findings, biopsy results, and CT staging carefully before recommending the appropriate extent of resection. Pre-operative nutritional optimisation is an important part of preparation for both procedures.

Q38: Can I eat normally after robotic gastrectomy?

Ans: Eating patterns change after gastrectomy and require permanent dietary adjustment. After distal gastrectomy — where the upper stomach is preserved — most patients can return to a near-normal diet over 3 to 6 months, though smaller meal portions and more frequent meals are advisable. After total gastrectomy, adaptation is more significant: patients require small, frequent meals throughout the day and must avoid large volumes of fluid with food to prevent early dumping syndrome. Nutritional supplementation — particularly Vitamin B12 (given by injection, as intrinsic factor is lost), iron, calcium, and fat-soluble vitamins — is a lifelong requirement after total gastrectomy. A clinical dietitian experienced in post-gastrectomy nutrition works alongside Dr. Gore's team at Sahyadri Manipal Hospital to guide patients through dietary recovery.

Q39: What is a robotic low anterior resection (LAR) for rectal cancer?

Ans: Robotic low anterior resection (LAR) is the surgical removal of the rectum for rectal cancer while preserving the anal sphincter complex — allowing the patient to avoid a permanent stoma. The rectum is removed along with its surrounding mesorectal fat and lymph nodes in a technique called total mesorectal excision (TME), which is the oncological gold standard. The bowel is then rejoined (anastomosed), usually with a temporary defunctioning loop ileostomy to protect the join during healing. The robotic approach offers a critical advantage for LAR in the narrow male pelvis — the wristed instruments and three-dimensional view allow more precise nerve-sparing dissection, lower conversion rates to open surgery, and better quality of TME compared to laparoscopic technique. A temporary stoma is typically reversed 2 to 3 months later.

Q40: Is robotic LAR better than laparoscopic LAR for low rectal cancer?

Ans: Several randomised trials and large observational studies have shown that robotic LAR for low rectal cancer — particularly in the narrow male pelvis — achieves lower rates of conversion to open surgery, better quality of mesorectal excision, and superior preservation of the autonomic nerves governing bladder and sexual function compared to laparoscopic LAR. The ROLARR trial demonstrated a lower conversion rate with robotic LAR, particularly in obese male patients with low rectal tumours. The superior articulation and stable camera platform of the robotic system are especially important when operating deep in the pelvis around the neurovascular bundles. For patients with low rectal cancer — where preserving urinary, sexual, and bowel function is critical — robotic surgery represents the preferred minimally invasive approach.

Q41: Will I need a permanent stoma after robotic rectal cancer surgery?

Ans: Most patients with rectal cancer undergoing robotic surgery do not require a permanent stoma, provided the tumour is located in the mid or upper rectum at a sufficient distance from the anal sphincter to allow safe resection with preservation of the sphincter mechanism. A temporary loop ileostomy — which diverts the faecal stream away from the new bowel join — is commonly fashioned during robotic LAR to allow the anastomosis to heal safely, and is typically reversed after 8 to 12 weeks once healing is confirmed by an imaging check. Very low rectal cancers involving or directly threatening the sphincter mechanism may still require an abdominoperineal resection (APR) with a permanent colostomy. Your surgical oncologist will determine the appropriate procedure based on the tumour's precise location, pre-operative MRI findings, and the response to any pre-operative chemoradiation.

Q42: What is a robotic APR (abdominoperineal resection)?

Ans: Robotic abdominoperineal resection (APR) is the surgical removal of the rectum, anal canal, anus, and surrounding sphincter muscles for very low rectal cancers or anal cancers where the tumour directly involves or is too close to the sphincter mechanism to allow safe preservation. The robotic abdominal component offers better visualisation within the deep pelvis, reduced blood loss, and greater precision around the pelvic nerves compared to open APR. A permanent end colostomy is created, through which bowel contents are collected into a stoma bag on the abdominal wall. The perineal component — closure of the pelvic floor after specimen removal — may be performed open or using a robotic transperineal approach. Stoma care education is an integral part of pre- and post-operative preparation.

Q43: Can robotic surgery preserve sphincter function in low rectal cancer?

Ans: In carefully selected patients with low rectal cancer, robotic surgery can achieve sphincter-preserving resection — avoiding a permanent colostomy — while maintaining full oncological safety. The technical precision of the robotic system, with its wristed instruments and magnified three-dimensional view, allows the surgeon to dissect closer to the sphincter complex with better accuracy than open or laparoscopic surgery. However, sphincter preservation is not possible in every case of low rectal cancer. If the tumour directly involves the sphincter muscles, or if achieving clear surgical margins while preserving the sphincter is not feasible, an abdominoperineal resection (APR) with permanent colostomy is the oncologically correct choice. Pre-operative MRI staging and discussion with your surgeon will clarify what is achievable in your individual case.

Q44: What is the cost of robotic colorectal cancer surgery in Pune?

Ans: The cost of robotic colorectal cancer surgery in Pune — including procedures such as robotic low anterior resection, robotic right or left hemicolectomy, robotic APR, and robotic total mesorectal excision — typically ranges from Rs 3 lakhs to Rs 6 lakhs. This estimate covers the surgical procedure, anaesthesia fees, robotic instrument consumables, ICU or high-dependency stay where required, ward accommodation, nursing care, and routine medications. It does not include pre-operative investigations, stoma bags and care products, post-operative chemotherapy or radiotherapy, or outpatient follow-up consultations. Cashless insurance arrangements are available at Sahyadri Manipal Hospital, Pune with prior TPA pre-authorisation. The hospital's billing and insurance team can provide an itemised estimate before admission.

Q45: How is robotic colon cancer surgery performed?

Ans: Robotic colon cancer surgery uses 4 to 5 small port incisions — inserted through the abdominal wall — through which the robotic camera and instruments are placed. The affected segment of colon, along with a margin of healthy bowel on either side and its draining lymph nodes and mesentery, is mobilised from the surrounding structures under direct three-dimensional visualisation. The blood supply to the diseased segment is divided, the bowel is freed, and the specimen is extracted through a small access incision that is also used for extracorporeal or intracorporeal anastomosis — rejoining the healthy bowel ends. In most cases, no stoma is required. Enhanced Recovery After Surgery (ERAS) protocols are applied to enable early mobilisation, rapid diet resumption, and discharge within 3 to 5 days of the operation.

Q46: What is robotic right hemicolectomy and left hemicolectomy?

Ans: Right hemicolectomy is the removal of the right colon — including the terminal ileum, caecum, ascending colon, and hepatic flexure — for cancers arising in the right side of the colon. Left hemicolectomy removes the descending colon and splenic flexure for cancers of the left colon. Both procedures are performed robotically using small port incisions, with magnified three-dimensional visualisation facilitating precise lymph node clearance around the ileocolic, right colic, and left colic vessels. These procedures achieve equivalent oncological outcomes to their open counterparts — in terms of R0 resection rate, lymph node harvest, and long-term survival — with the well-established advantages of robotic minimally invasive surgery: less blood loss, shorter hospital stay, and significantly faster recovery.

Q47: How many days hospital stay after robotic colectomy?

Ans: Hospital stay after robotic colon cancer surgery (colectomy) is typically 3 to 5 days, compared to 7 to 10 days after equivalent open colon surgery. This shorter stay is made possible by the enhanced recovery protocols applied at Sahyadri Manipal Hospital — early removal of the urinary catheter, early oral fluid and diet resumption, proactive pain management using multimodal non-opioid analgesia, and early supervised mobilisation from the first post-operative day. Patients are generally able to eat soft food by Day 2, walk independently by Day 2 or 3, and are discharged with clear instructions for home recovery. After discharge, most patients are able to resume normal household activities within 1 to 2 weeks and return to desk work within 3 to 4 weeks of robotic colon surgery.

Q48: Can robotic surgery treat liver metastases from colon cancer?

Ans: Robotic liver resection for colorectal liver metastases is performed at select specialised hepatopancreaticobiliary (HPB) centres. When colorectal cancer has spread to the liver but the metastases are resectable — meaning limited in number and location, with adequate functional liver volume remaining — surgical removal of liver metastases (hepatic metastasectomy) offers the best chance of long-term cure. Robotic hepatectomy for colorectal liver metastases is feasible and increasingly performed, offering reduced blood loss and faster recovery compared to open liver resection. In some centres, a combined simultaneous robotic colectomy and hepatectomy is performed in a single anaesthetic for synchronous colorectal liver metastases. Resectability depends on the number, size, distribution, and relationship of metastases to the hepatic veins and portal structures.

Q49: Is robotic surgery good for early-stage stomach cancer?

Ans: Yes. Robotic gastrectomy is an excellent choice for early gastric cancer — Stage T1 and T2 tumours — offering equivalent oncological outcomes to open gastrectomy with the well-established benefits of minimally invasive surgery. A critical quality benchmark for gastric cancer surgery is the retrieval of an adequate number of lymph nodes for pathological staging — at least 16 nodes according to international guidelines. Robotic D2 lymphadenectomy consistently achieves adequate nodal harvest in experienced hands, with published data confirming equivalence to open D2 gastrectomy. For early gastric cancer, particularly in younger and middle-aged patients for whom a faster return to work and reduced post-operative complications are especially important, robotic gastrectomy is increasingly the preferred surgical approach at experienced centres.

Q50: What is the recovery diet after robotic GI cancer surgery?

Ans: Dietary recovery after robotic GI cancer surgery varies by the specific procedure. After robotic colectomy, most patients resume a normal diet within 1 to 2 weeks. After robotic gastrectomy, a progressive soft diet over 6 to 8 weeks — with lifelong small, frequent meals — is required, along with Vitamin B12 and iron supplementation after total gastrectomy. After robotic Whipple surgery, pancreatic exocrine insufficiency commonly develops, requiring oral pancreatic enzyme replacement therapy (Creon) with every meal to support fat digestion and nutritional absorption. After robotic esophagectomy, swallowing retraining and gradual diet progression are supervised by a speech and language therapist and dietitian. A clinical dietitian experienced in upper GI oncology recovery is an integral part of Dr. Gore's patient care team at Sahyadri Manipal Hospital.

Q51: Can robotic surgery be done after chemotherapy or radiation?

Ans: Yes. Robotic surgery after neoadjuvant (pre-operative) chemotherapy or chemoradiation is safe and routinely practised. For rectal cancer, robotic LAR or APR following chemoradiation is standard — the pre-operative treatment shrinks the tumour and may downstage it, improving the prospects of sphincter preservation and clear surgical margins. For oesophageal cancer, robotic esophagectomy following chemoradiation (CROSS or FLOT regimen) is well-established. For gastric cancer, neoadjuvant FLOT chemotherapy followed by robotic gastrectomy is increasingly practised. Prior chemotherapy and radiation cause tissue changes — including fibrosis, oedema, and altered tissue planes — that an experienced robotic surgical oncologist is specifically trained to navigate. Dr. Vinod Gore's extensive training at Tata Memorial Hospital included post-chemoradiation surgery across all GI sites.

Q52: What is the role of robotic surgery in gallbladder cancer?

Ans: Robotic surgery for gallbladder cancer is appropriate for selected cases — most commonly incidental gallbladder cancers detected on histopathology after laparoscopic cholecystectomy for presumed benign disease. When the pathology reveals a T1b or higher gallbladder cancer, a re-resection is required: robotic extended cholecystectomy including a 2cm margin of liver bed and regional lymphadenectomy of the hepatoduodenal ligament nodes. For gallbladder cancers presenting with a mass on imaging — particularly those involving the liver, bile duct, or duodenum — open surgery is typically required for adequate radical resection. The key oncological concern with gallbladder cancer after prior laparoscopic cholecystectomy is peritoneal dissemination; careful review of the original laparoscopy notes and port sites is essential before planning re-resection.

Q53: Pet ke cancer ki surgery robotic se kaise hoti hai?

Ans: Pet ke cancer — jaise colon ka cancer, rectum ka cancer, stomach ka cancer, ya pancreas ka cancer — mein robotic surgery is tarah ki jaati hai: surgeon console par baithkar chhote chhote haath control karta hai jo patient ke pet mein sirf 8 se 12mm ke chhedon ke zariye daale jaate hain. Ek high-definition 3D camera andar ki poori tasveer surgeon ko dikhata hai. Cancer aur uske aas-paas ke lymph nodes ko sahi tarike se nikala jaata hai — bilkul waisi hi saaf surgery jaisi open surgery mein hoti hai — lekin bina bade chiire ke. Isliye khoon bahut kam nikalta hai, dard kam hota hai, hospital mein sirf 3 se 5 din rehna padta hai, aur patient bahut jaldi ghar jaata hai. Dr. Vinod Gore, Sahyadri Manipal Hospital, Pune mein yeh sab surgeries karte hain.

Q54: Is robotic surgery recommended for GIST (gastrointestinal stromal tumours)?

Ans: Yes. Robotic surgery is an excellent approach for gastrointestinal stromal tumour (GIST) resection, particularly for gastric GISTs — which are the most common location — and small intestinal GISTs. The key oncological principle governing GIST resection is intact removal without tumour rupture, as rupture dramatically worsens prognosis by causing peritoneal seeding. The robotic system's superior visualisation and atraumatic instrument handling make it well-suited to achieving intact en-bloc resection while minimising the risk of capsule disruption. Lymph node dissection is generally not required for GIST, unlike epithelial gastric cancers. Large GISTs — particularly those with dense vascular supply — may be better approached via open surgery. GISTs are treated in conjunction with imatinib (Gleevec) targeted therapy, which may be given pre-operatively to shrink larger tumours before surgery.

Q55: What are the long-term outcomes after robotic GI cancer surgery?

Ans: Long-term oncological outcomes after robotic GI cancer surgery are equivalent to open surgery across all well-studied cancer types. For colorectal cancer, multiple randomised controlled trials including the COREAN, COLOR II, and ACOSOG Z6051 trials confirm equivalent 3-year and 5-year disease-free and overall survival for robotic and open surgery. For gastric cancer, the KLASS and ADORE trials support equivalent long-term survival for robotic versus open gastrectomy in early and locally advanced disease. Pancreatic cancer survival data after robotic Whipple is broadly consistent with open Whipple in experienced centres. The primary advantages of robotic surgery — which are unequivocal — are in the short-term perioperative outcomes: blood loss, complication rate, length of stay, and speed of functional recovery.

Q56: What is robotic lung cancer surgery (RATS)?

Ans: Robot-Assisted Thoracic Surgery (RATS) is the minimally invasive removal of lung tissue — a lobe, a segment, or a wedge — for primary lung cancer or pulmonary metastases using a surgeon-controlled robotic system. Instead of the conventional open thoracotomy, which requires a large incision between the ribs and spreading of the rib cage — causing significant post-operative pain and prolonged recovery — RATS uses 3 to 4 small chest port incisions. The robotic system's three-dimensional magnified view and wristed instruments allow precise dissection of the hilar structures, stapling of pulmonary vessels and bronchi, and thorough mediastinal lymph node dissection — all through ports that avoid rib-spreading and dramatically reduce chest wall trauma. Dr. Vinod Gore performs robotic thoracic oncosurgery at Sahyadri Manipal Hospital, Pune.

Q57: How is robotic lobectomy different from VATS lobectomy?

Ans: Both robotic (RATS) and video-assisted thoracoscopic (VATS) lobectomy are minimally invasive approaches to lung cancer surgery that avoid open thoracotomy. The key differences lie in visualisation, instrument dexterity, and ergonomics. VATS uses a flat two-dimensional camera and rigid long instruments that are difficult to manoeuvre in the confines of the chest. Robotic lobectomy provides a fully immersive magnified three-dimensional view and articulated instruments with seven degrees of freedom — mimicking the natural movement of the human wrist inside the chest. This is particularly advantageous during complex hilar dissection, division of calcified or adherent lymph nodes, and bronchial sleeve resections. For surgeons, the ergonomic console also reduces fatigue during long thoracic procedures. In centres with robotic expertise, robotic lobectomy consistently demonstrates lower conversion rates and equivalent or superior lymph node yield to VATS.

Q58: Is robotic lobectomy available in Pune for lung cancer?

Ans: Yes. Robotic thoracic oncosurgery — including robotic lobectomy, segmentectomy, and mediastinal tumour resection — is available at Sahyadri Manipal Hospital, Pune. Dr. Vinod Gore, Department Head Surgical Oncology, completed a dedicated Research Fellowship in Thoracic Oncology at Tata Memorial Hospital, Mumbai — India's premier cancer institution — and maintains a prospective database of 100 or more pulmonary metastasectomy cases. He holds the FARIS (Fellowship in Advanced Robotic and Innovative Surgery) from the University of Edinburgh and leads a Robotic Surgery Centre of Excellence at Sahyadri Manipal Hospital. Patients from Pune and across Maharashtra requiring robotic lung cancer surgery can consult at Silver Leaf Clinic, Hadapsar, or at Sahyadri Manipal Hospital directly.

Q59: What are the benefits of robotic lung surgery for early-stage lung cancer?

Ans: For patients with early-stage lung cancer — Stage I and Stage II — robotic lobectomy or segmentectomy offers several meaningful advantages over open thoracotomy. The most significant is the dramatic reduction in chest wall trauma: without rib-spreading, post-operative pain is greatly reduced, shoulder mobility is better preserved, and the risk of post-thoracotomy pain syndrome — a chronic pain condition affecting many open thoracotomy patients — is minimised. Chest drain duration is shorter after robotic surgery, enabling faster discharge. Pulmonary function recovery is better because the chest wall muscles are not cut. Long-term cancer control outcomes — disease-free survival and overall survival — are equivalent to open lobectomy for Stage I–II lung cancer. Patients who might not tolerate an open thoracotomy due to cardiopulmonary comorbidity may be candidates for robotic minimally invasive surgery.

Q60: How long is the hospital stay after a robotic lobectomy?

Ans: Hospital stay after robotic lobectomy for lung cancer is typically 3 to 5 days, compared to 7 to 10 days after conventional open thoracotomy. The key determinant of discharge timing is the removal of the chest drain — which is done once the lung has re-expanded fully and drainage of air and fluid has become minimal, usually within 1 to 3 days after robotic surgery. Without rib-spreading and with less chest wall muscle disruption, patients mobilise much earlier after robotic lobectomy, reducing the risk of deep vein thrombosis, hospital-acquired pneumonia, and deconditioning. At Sahyadri Manipal Hospital, Pune, enhanced recovery protocols for thoracic surgery are applied to facilitate the earliest safe discharge, minimising the risk of hospital-related complications.

Q61: Will I have a chest tube after robotic lung surgery, and for how long?

Ans: Yes. A chest drain (intercostal tube) is placed at the end of robotic lung surgery to remove air and fluid from the pleural cavity as the lung re-expands. This is standard practice after all thoracic procedures, both open and robotic. After robotic lobectomy, the drain is typically removed within 1 to 3 days, once a chest X-ray confirms complete lung expansion and drainage has reduced to a minimal level. Robotic thoracic surgery is associated with shorter chest drain duration and lower total drain output than open thoracotomy, because chest wall trauma is significantly less. Early drain removal directly contributes to improved patient comfort, earlier mobilisation, reduced analgesic requirements, and shorter overall hospital stay after lung cancer surgery.

Q62: Can robotic surgery remove a single lung lobe (lobectomy) safely?

Ans: Yes. Robotic lobectomy — the removal of one of the five lung lobes — is a well-established, safe, and standard procedure for early-stage non-small-cell lung cancer. The right lung has three lobes (upper, middle, lower) and the left lung has two (upper, lower). Robotic lobectomy achieves the same oncological completeness as open lobectomy — complete removal of the lobe, its bronchus, and all draining hilar and mediastinal lymph node stations — through 3 to 4 small chest port incisions. The robotic system's three-dimensional view and articulated instruments provide exceptional access to the hilar structures. Robotic lobectomy is now the preferred surgical approach for lung cancer resection at major robotic thoracic surgery programmes worldwide, including Sahyadri Manipal Hospital, Pune.

Q63: What is robotic segmentectomy and when is it preferred over lobectomy?

Ans: Robotic segmentectomy removes only the anatomical lung segment containing the cancer — preserving the remaining segments of that lobe — rather than removing the entire lobe as in lobectomy. This lung-preserving approach is preferred in specific clinical situations: small peripheral tumours measuring 2cm or less in maximum diameter, particularly ground-glass opacity (GGO) or part-solid nodules that have a favourable biology; elderly patients or those with reduced pre-operative lung function who may not tolerate the functional loss of a full lobectomy; and patients with prior lung surgery or contralateral lung disease. The JCOG0802 trial and the CALGB140503 trial have both confirmed oncological equivalence of segmentectomy to lobectomy for select T1a and T1b non-small-cell lung cancers. Robotic segmentectomy requires precise knowledge of pulmonary anatomy and is best performed by experienced thoracic oncosurgeons.

Q64: What is robotic wedge resection of the lung?

Ans: Robotic wedge resection is the removal of a small, wedge-shaped portion of the lung — including the tumour and a margin of surrounding normal tissue — without regard to anatomical segment or lobe boundaries. It is the most lung-tissue-preserving approach to pulmonary resection. Robotic wedge resection is typically used in three clinical situations: removal of small peripheral primary lung cancers in high-risk patients who cannot tolerate a larger resection; pulmonary metastasectomy — removal of one or more metastatic deposits in the lung from a primary cancer elsewhere (such as colorectal, breast, or sarcoma); and diagnostic excision of an indeterminate lung nodule where CT-guided biopsy has been inconclusive. Dr. Vinod Gore has extensive experience in pulmonary metastasectomy, maintaining a prospective database of over 100 cases at Sahyadri Manipal Hospital.

Q65: Is robotic surgery good for mediastinal tumours and thymoma?

Ans: Yes. Robotic surgery is one of the most advantageous approaches for mediastinal tumours — particularly anterior mediastinal tumours such as thymoma, which are the most common surgically resectable mediastinal masses. The robotic system provides exceptional access to the anterior mediastinum through small lateral chest port incisions, avoiding the traditional median sternotomy (splitting of the breast bone) which carries significant post-operative pain and a 6 to 8 week recovery. Robotic thymectomy achieves equivalent tumour clearance to open sternotomy-based resection for Masaoka Stage I–II thymoma, with published studies confirming complete resection rates and long-term oncological outcomes comparable to open surgery. Other mediastinal masses amenable to robotic resection include mature teratoma, lymphoma (for diagnostic biopsy), posterior mediastinal neurogenic tumours, and mediastinal cysts.

Q66: What is a robotic thymectomy and who needs it?

Ans: Robotic thymectomy is the minimally invasive surgical removal of the thymus gland, performed for two main indications: thymoma — a cancer of the thymus gland that is the most common anterior mediastinal tumour in adults — and myasthenia gravis, an autoimmune neuromuscular condition where thymectomy (even in the absence of thymoma) has been shown in randomised trials to improve symptoms and reduce the need for immunosuppressive medication. Robotic thymectomy is performed through 3 small ports placed in the lateral chest wall, avoiding the median sternotomy incision. The entire thymus gland — including all anterior mediastinal fat — must be removed for both oncological and myasthenia gravis indications. Post-operative pain is significantly less than after sternotomy, and patients typically return to full activity within 2 to 3 weeks.

Q67: Can robotic surgery treat anterior mediastinal masses?

Ans: Yes. The anterior mediastinum — the space between the sternum and the heart — is the most common location for primary mediastinal tumours in adults. Robotic surgery is an excellent approach for resecting anterior mediastinal masses including thymoma and thymic carcinoma, mature teratoma and germ cell tumours (benign variants), thymolipoma, and select cases of primary mediastinal lymphoma requiring biopsy for diagnosis. The robotic system provides a magnified three-dimensional view of the anterior mediastinal structures — including the pericardium, phrenic nerves, great vessels, and superior vena cava — allowing precise dissection with minimal risk of inadvertent injury. Tumours adherent to or invading adjacent structures may require open or combined approaches; CT staging determines resectability before planning the operative approach.

Q68: How painful is recovery after robotic lung cancer surgery?

Ans: Pain after robotic lung cancer surgery is significantly less than after conventional open thoracotomy, which is well-recognised as one of the most painful surgical procedures due to the rib-spreading required for access. Without rib-spreading, the intercostal nerves are not stretched or compressed, dramatically reducing post-operative pain intensity. Most patients undergoing robotic lobectomy require only oral pain medication — paracetamol, NSAIDs, and occasionally mild opioids — within 48 to 72 hours of surgery. Robotic thoracic surgery patients are also much less likely to develop post-thoracotomy pain syndrome — a chronic pain condition where persistent chest wall pain continues for months or years after open surgery — which is a significant quality-of-life advantage particularly for younger patients.

Q69: When can I climb stairs and exercise after robotic lobectomy?

Ans: Most patients are able to climb stairs comfortably within 1 to 2 weeks after robotic lobectomy, compared to 4 to 6 weeks after open thoracotomy. Light walking — on flat ground — is encouraged from the first post-operative day in hospital as part of the early mobilisation protocol. After discharge, a structured pulmonary rehabilitation programme is recommended to optimise the recovery of breathing capacity and shoulder function, which can be affected by the chest port incisions. Gentle cardiovascular exercise such as walking is built up progressively over 4 to 6 weeks. Most patients are able to return to full physical activity — including swimming, gym, and running — within 6 to 8 weeks of robotic lobectomy. Your surgeon and physiotherapist will provide an individualised exercise recovery programme.

Q70: What is the cost of robotic lung cancer surgery in India?

Ans: Robotic lobectomy for lung cancer in India typically costs between Rs 3.5 lakhs and Rs 7 lakhs, depending on the hospital, city, and the specific procedure — lobectomy versus segmentectomy versus wedge resection — and the duration of ICU and ward stay. This estimate covers the surgical procedure, anaesthesia, robotic consumables, chest drain management, ICU monitoring if required, ward accommodation, and standard medications. At Sahyadri Manipal Hospital, Pune, the billing team provides a detailed pre-admission cost estimate. Most comprehensive health insurance policies — including group health cover and individual mediclaim — cover robotic thoracic surgery with prior TPA pre-authorisation. CGHS, ECHS, and MJPJAY coverage is also available for eligible patients. Contact the hospital's insurance desk for specific guidance.

Q71: Will my lung function reduce after robotic lobectomy?

Ans: Removal of a lung lobe does cause a measurable reduction in overall lung function — typically in the range of 10 to 20 percent of pre-operative FEV1 and FVC values — because the functional lung volume is permanently reduced. However, the remaining lung tissue compensates over time through a process of compensatory expansion, and many patients find that their functional breathing capacity stabilises at a level well compatible with normal daily activities and moderate exercise. Robotic lobectomy causes less additional functional loss than open lobectomy because the chest wall muscles are not cut — preserving shoulder and respiratory muscle function. Pre-operative pulmonary function testing (spirometry and DLCO) is performed before all thoracic cancer surgeries to assess fitness for resection and to predict post-operative lung function.

Q72: Is robotic surgery safe for smokers with lung cancer?

Ans: Yes, with appropriate pre-operative optimisation. The majority of lung cancer patients are current or former smokers, and robotic lobectomy is routinely performed in this group. Smokers are strongly advised to stop smoking completely at least 4 to 6 weeks before lung surgery — even this relatively short period of smoking cessation significantly improves bronchial mucosal function, reduces secretions, and lowers the risk of post-operative pulmonary complications including pneumonia and prolonged air leak. Pre-operative pulmonary function tests, a 6-minute walk test, and sometimes a cardiopulmonary exercise test (CPET) are performed to assess fitness for resection. The robotic approach's reduced chest wall trauma is particularly beneficial for smokers with co-existing COPD or reduced lung reserve, enabling resection that might not be safely achievable through open thoracotomy.

Q73: Can robotic surgery treat lung cancer that has spread to lymph nodes?

Ans: Robotic surgery with systematic mediastinal lymph node dissection (MLND) is appropriate for Stage I, Stage II, and selected Stage IIIA non-small-cell lung cancers where the disease has spread to hilar or ipsilateral mediastinal lymph nodes. Thorough lymph node removal — across all mediastinal stations — is a critical component of lung cancer surgery for both accurate pathological staging and potential therapeutic benefit. Robotic thoracic surgery achieves equivalent or superior mediastinal lymph node harvest to open thoracotomy in experienced centres. Stage IIIB disease (contralateral mediastinal nodes, supraclavicular nodes) is generally not treated with primary surgery; concurrent chemoradiation is the standard approach. All staging decisions are based on a combination of pre-operative CT, PET-CT, and endobronchial ultrasound (EBUS) findings.

Q74: How many lymph nodes are removed during robotic lung cancer surgery?

Ans: Current international guidelines — including those from the European Society of Thoracic Surgeons (ESTS) and the American College of Surgeons Oncology Group (ACOSOG) — recommend systematic sampling or complete dissection of at least 6 lymph node stations during lung cancer resection: at least 3 hilar stations (N1 nodes) and at least 3 mediastinal stations (N2 nodes), including the subcarinal station. The robotic system's magnified three-dimensional view and precise instrument control facilitate thorough nodal dissection — allowing the surgeon to safely remove nodes from stations that may be difficult to access via VATS or laparoscopic thoracic surgery. Adequate lymph node harvest directly determines staging accuracy and influences the decision on adjuvant chemotherapy, which is beneficial for Stage II and Stage III disease.

Q75: Phephde ke cancer ki robotic surgery kahan hoti hai Pune mein?

Ans: Phephde ke cancer — yaani lung cancer — ki robotic surgery Pune mein Sahyadri Manipal Hospital mein hoti hai, jahan Dr. Vinod Gore ek dedicated thoracic oncosurgery programme lead karte hain. Dr. Gore Tata Memorial Hospital se trained hain — unhone wahan ek Research Fellowship in Thoracic Oncology ki thi — aur unke paas University of Edinburgh ka FARIS fellowship bhi hai. Sahyadri Manipal Hospital ka yeh programme ek recognised Robotic Surgery Centre of Excellence hai. Yahan robotic lobectomy, segmentectomy, aur mediastinal tumour removal jaisi surgeries ki jaati hain. 100 se zyada pulmonary metastasectomy cases ka prospective database bhi maintain kiya jaata hai. Appointment ke liye Silver Leaf Clinic, Hadapsar, Pune mein sampark karein ya +91 84118 08284 pe call karein.

Q76: What is robotic breast cancer surgery?

Ans: Robotic breast cancer surgery performs mastectomy — removal of all breast tissue — through small incisions hidden in the armpit or lateral chest wall, rather than the traditional incision across the front of the breast. Using the robotic system's magnified three-dimensional view and articulated instruments, the surgeon removes all breast tissue from beneath the skin in a precisely controlled manner — achieving the same oncological completeness as conventional mastectomy but without the visible chest wall scar. This approach combines the oncological rigour of mastectomy with superior cosmetic outcomes. Immediate breast reconstruction — using an implant, tissue expander, or autologous flap — can be performed in the same operation, allowing the patient to wake up with preserved breast shape and no visible breast scar.

Q77: Is robotic mastectomy available in Pune?

Ans: Yes. Robotic breast cancer surgery — including robotic nipple-sparing mastectomy and skin-sparing mastectomy — is available in Pune. Dr. Vinod Gore has extensive and specialised training in both surgical oncology and oncoplastic breast surgery, complemented by a three-year plastic and reconstructive surgery training at Sassoon General Hospital, B.J. Medical College, Pune. He performs robotic breast procedures at Sahyadri Manipal Hospital — a recognised Robotic Surgery Centre of Excellence — and consults at Silver Leaf Clinic, 511 City Centre, Solapur Road, Hadapsar, Pune. This dual training in oncology and reconstruction makes Dr. Gore uniquely qualified to offer comprehensive robotic breast cancer care combining complete tumour removal with optimal cosmetic and functional outcomes.

Q78: What is a robotic nipple-sparing mastectomy?

Ans: Robotic nipple-sparing mastectomy (NSM) removes all breast tissue — including the breast parenchyma, ducts, and retro-areolar tissue — while preserving the nipple-areola complex and all overlying breast skin. The operation is performed through a small incision hidden in the axilla (armpit), using robotic instruments to dissect all breast tissue from beneath the skin flaps in the plane between skin and breast. NSM is oncologically appropriate for early-stage breast cancers located away from the nipple, where pre-operative MRI and biopsy confirm the nipple-areola complex is uninvolved. It is also used for prophylactic risk-reduction mastectomy in BRCA gene carriers or those with strong family history. Immediate implant-based or autologous reconstruction is typically performed simultaneously, giving excellent cosmetic outcomes.

Q79: What is a robotic skin-sparing mastectomy?

Ans: Robotic skin-sparing mastectomy (SSM) removes all breast tissue and the nipple-areola complex but preserves the breast skin envelope — the natural skin covering of the breast. The preserved skin envelope creates an ideal, well-vascularised pocket into which an implant or autologous tissue reconstruction can be placed immediately, producing a significantly better cosmetic outcome than conventional mastectomy which removes most of the breast skin. SSM is oncologically safe for most invasive breast cancers where the skin is not involved by tumour. The robotic approach — using a small lateral or axillary incision — provides excellent visualisation for thorough subcutaneous breast tissue removal while preserving the skin flap integrity. Skin-sparing mastectomy is particularly appropriate for immediate implant-based reconstruction in patients with good skin quality.

Q80: Can robotic surgery be used for breast conservation surgery (BCS)?

Ans: Robotic technology is being explored in the context of breast conservation surgery (BCS) — also called lumpectomy or wide local excision — but it is not yet the established standard for routine BCS. In specific situations — such as tumours located deep within the breast that are difficult to access through conventional BCS, or in cases where robotic access enables a more precise cavity assessment — robotic assistance may offer an advantage. However, for the majority of patients requiring breast conservation surgery, the conventional or oncoplastic approach remains the standard of care. Dr. Gore's particular strength in oncoplastic breast surgery — combining cancer removal with immediate tissue rearrangement — allows excellent cosmetic outcomes for breast conservation without the added complexity of robotic access in most cases.

Q81: What is robotic oncoplastic breast surgery?

Ans: Robotic oncoplastic breast surgery integrates the principles of oncoplastic surgery — which combines cancer removal with immediate breast reshaping and reconstruction — with the technical advantages of the robotic approach. Dr. Vinod Gore's unique combination of surgical oncology training at Tata Memorial Hospital and three years of plastic and reconstructive surgery experience at Sassoon General Hospital and B.J. Medical College gives him a breadth of expertise that is rare among Indian surgical oncologists. This enables him to offer personalised robotic breast cancer surgery plans that optimise both oncological safety — achieving clear surgical margins — and cosmetic outcomes, including nipple-sparing mastectomy with immediate implant reconstruction, robotic-assisted LD flap harvest, and oncoplastic volume displacement techniques for breast conservation.

Q82: Will I have a visible scar on my breast after robotic mastectomy?

Ans: No. One of the most significant advantages of robotic mastectomy compared to conventional mastectomy is the complete absence of a visible scar on the breast. In robotic nipple-sparing or skin-sparing mastectomy, the surgical access is through a small incision hidden in the armpit — typically 3 to 5cm — or in the lateral chest wall. All breast tissue removal is performed robotically through this concealed access, leaving no scar on the breast itself. This has profound implications for a patient's body image, self-confidence, and psychological recovery after breast cancer surgery. For young women, professionals, or anyone for whom the cosmetic impact of mastectomy is a significant concern, robotic mastectomy with immediate reconstruction offers a transformative alternative to the visible scar of conventional surgery.

Q83: How is robotic breast surgery different from conventional mastectomy?

Ans: Conventional mastectomy uses a horizontal or oblique incision directly across the breast — typically 15 to 20cm — leaving a permanent visible scar on the chest. All breast tissue is removed through this incision under direct vision. Robotic mastectomy, by contrast, uses a small axillary or lateral chest access incision through which robotic instruments are introduced to remove breast tissue from a distance, using the three-dimensional magnified camera for visualisation. The result is equivalent oncological breast tissue removal — confirmed by post-mastectomy specimen weight analysis and histopathology — with no breast scar and a markedly improved cosmetic outcome. Immediate reconstruction — with an implant or autologous tissue — is performed in the same sitting, and the patient wakes with preserved breast contour and no visible chest wall incision.

Q84: Can robotic surgery do immediate breast reconstruction with implant?

Ans: Yes. Immediate implant-based breast reconstruction is routinely combined with robotic nipple-sparing or skin-sparing mastectomy in a single operation. After the robotic removal of all breast tissue through the axillary access incision, the preserved skin envelope and subcutaneous space is used to accommodate a breast implant or tissue expander placed beneath the pectoralis major muscle. The absence of a breast scar and the preserved natural breast skin envelope produce an excellent cosmetic result that is significantly better than delayed reconstruction or reconstruction through a scarred mastectomy field. Immediate reconstruction avoids a second operation, reduces the psychological impact of mastectomy by preserving body image from the outset, and does not delay the start of adjuvant chemotherapy or radiation if required.

Q85: What is robotic-assisted DIEP flap reconstruction?

Ans: The Deep Inferior Epigastric Perforator (DIEP) flap is an advanced autologous breast reconstruction technique that uses skin, fat, and the tiny perforator blood vessels from the lower abdomen to reconstruct the breast — without sacrificing the rectus abdominis muscle. Robotic-assisted DIEP flap harvest uses robotic access to identify and carefully dissect the perforator vessels from within the muscle — significantly reducing muscle trauma, post-operative abdominal wall weakness, and donor-site morbidity compared to conventional open DIEP dissection. The dissected flap is then transferred microsurgically to the chest wall. This technically complex approach requires specialised training in both robotic surgery and microsurgery, and represents the most advanced level of robotic breast reconstruction. Dr. Gore's plastic surgery training provides the reconstructive foundation for these procedures.

Q86: Can robotic surgery harvest a latissimus dorsi flap for breast reconstruction?

Ans: Yes. Robotic endoscopic latissimus dorsi (LD) flap harvest is a well-established technique that avoids the conventional large back incision — typically 15 to 20cm — required for open LD muscle harvest for breast reconstruction. Using 3 small port incisions on the back, the robotic system provides a magnified view of the LD muscle and allows precise division of its humeral attachment and mobilisation from the surrounding tissues, with the thoracodorsal vascular pedicle preserved intact. The muscle and overlying fat paddle are then tunnelled beneath the axillary skin to the mastectomy site. Robotic LD harvest significantly reduces the donor-site scar, post-operative back pain, shoulder mobility restriction, and risk of seroma compared to conventional open harvest — providing equivalent volume and vascularity for breast reconstruction.

Q87: Is robotic breast surgery safe oncologically — does it remove all cancer?

Ans: Yes. Oncological safety — achieving complete removal of all breast tissue without residual cancer — is the paramount concern of robotic mastectomy, and published studies confirm that robotic mastectomy achieves equivalent oncological outcomes to conventional open mastectomy. The key measures are residual breast tissue volume (assessed by weighing the mastectomy specimen and comparing with pre-operative MRI volume estimates), the status of surgical margins on histopathology, and local recurrence rates in long-term follow-up. Multiple published series — predominantly from Korean and European centres where robotic mastectomy has been most widely adopted — confirm that specimen weight, margin status, and medium-term local recurrence rates are comparable between robotic and open mastectomy in appropriately selected patients. Patient selection and surgeon experience are the critical determinants of oncological safety.

Q88: Does robotic breast surgery preserve nipple sensation?

Ans: Nipple sensation after nipple-sparing mastectomy — whether performed robotically or by conventional approach — is partially preserved in most patients. However, a degree of sensory change is expected and should be discussed honestly before surgery. During mastectomy, the terminal branches of the fourth intercostal nerve — which supply sensation to the nipple-areola complex — are inevitably disrupted as the breast tissue is cleared from beneath the skin. The extent of sensory preservation depends on the specific nerve anatomy, the thoroughness of breast tissue removal required, and the surgical technique. Robotic NSM may offer some advantage in sensory preservation by allowing a more controlled dissection around the areolar margin, but this benefit is not yet definitively established in comparative studies. Nerve-sparing mastectomy techniques and sensory regenerative procedures are evolving areas of reconstructive oncoplastic surgery.

Q89: How long is recovery after robotic mastectomy compared to conventional?

Ans: Recovery after robotic mastectomy is generally faster and associated with less pain than after conventional open mastectomy. Hospital stay after robotic mastectomy is typically 2 to 3 days — compared to 3 to 5 days for conventional mastectomy with reconstruction. Return to light daily activities is usually possible within 1 to 2 weeks for robotic mastectomy patients, compared to 3 to 4 weeks after conventional surgery. The axillary drain — placed to collect lymphatic fluid — is the main determinant of discharge timing and is removed once output falls below 30ml per day, typically within 5 to 10 days. Shoulder mobilisation exercises are started early to prevent post-mastectomy shoulder stiffness. Full return to normal physical activity, including driving and lifting, is typically achieved within 4 to 6 weeks of robotic mastectomy.

Q90: What is the cost of robotic breast cancer surgery in India?

Ans: Robotic mastectomy for breast cancer in India costs approximately Rs 2.5 lakhs to Rs 5 lakhs, depending on whether immediate reconstruction is performed and the type of reconstruction chosen — implant-based versus autologous flap. Implant-based immediate reconstruction adds the cost of the implant, which typically ranges from Rs 50,000 to Rs 2 lakhs depending on the implant brand, profile, and size. Most major health insurance policies in India cover mastectomy for breast cancer; the robotic component may attract a consumables charge that varies by policy. It is important to obtain a written pre-authorisation from your TPA confirming coverage before scheduling the procedure. The billing team at Sahyadri Manipal Hospital can provide a detailed, itemised pre-admission cost estimate.

Q91: Can robotic surgery do axillary lymph node dissection?

Ans: Yes. Robotic axillary lymph node dissection (ALND) — removal of the Level I and II axillary lymph nodes for staging and treatment of breast cancer — can be performed through the same small axillary incision used for robotic mastectomy access. This avoids the need for an additional separate axillary incision, which is required in conventional mastectomy with axillary clearance. The robotic system's magnified view allows excellent visualisation of the axillary vein, long thoracic nerve, thoracodorsal neurovascular bundle, and intercostobrachial nerves during lymph node dissection — facilitating nerve preservation and reducing post-operative numbness, shoulder weakness, and lymphoedema risk. Sentinel lymph node biopsy using ICG fluorescence can also be performed robotically before proceeding to full axillary clearance if sentinel node assessment is planned.

Q92: Is robotic surgery good for early-stage breast cancer (Stage 1 and 2)?

Ans: Yes. Robotic nipple-sparing mastectomy is most commonly and most effectively used for early-stage breast cancer — Stage I and Stage II — where the tumour is small relative to the breast volume, not involving the skin or nipple-areola complex, and located at a safe distance from the nipple margin on pre-operative MRI. It is also the preferred approach for risk-reduction (prophylactic) mastectomy in BRCA1 and BRCA2 gene carriers who choose bilateral mastectomy. For larger Stage II tumours where nipple-sparing is oncologically borderline, the decision is individualised based on tumour biology, size, location, and MRI findings. Robotic mastectomy is generally not appropriate for Stage III inflammatory breast cancer or locally advanced disease with skin involvement.

Q93: Can a patient with large breasts undergo robotic mastectomy?

Ans: Robotic mastectomy is technically more challenging in patients with large, ptotic (drooping) breasts, or breast volumes above approximately 600 to 800ml. In these cases, the robotic access through a small axillary incision requires the instruments to work across a larger distance and through a greater volume of tissue — increasing operating time and the technical demands on the surgeon. Patient selection for robotic mastectomy should therefore include an assessment of breast size, tissue density, degree of ptosis, tumour location, skin quality, and reconstruction plan. In patients with large breasts planning immediate implant reconstruction after robotic mastectomy, a contralateral reduction mammaplasty for symmetry may also be planned. Your surgeon at Sahyadri Manipal Hospital will advise honestly on whether the robotic approach is technically optimal for your specific case.

Q94: Will I need chemotherapy or radiation after robotic breast surgery?

Ans: The need for chemotherapy, hormone therapy, targeted therapy, or radiation after breast cancer surgery is determined entirely by the biological characteristics of your cancer — specifically the stage, tumour grade, hormone receptor status (ER, PR), HER2 status, and Ki-67 proliferation index — as well as the presence or absence of lymph node involvement. These factors are independent of whether mastectomy is performed robotically or by conventional technique. Robotic mastectomy does not change the indications for adjuvant treatment. Post-mastectomy radiation therapy is indicated when the axillary nodes are positive, when the tumour is large (T3/T4), or when margins are close or involved. All adjuvant treatment decisions are made by the oncology team after reviewing the complete post-operative histopathology report.

Q95: Breast cancer ki robotic surgery ka kharcha kitna hota hai?

Ans: Breast cancer ki robotic mastectomy — jisme chhupte huye axillary incision se poori breast tissue nikali jaati hai — India mein approximately Rs 2.5 lakh se Rs 5 lakh tak hoti hai. Yeh cost surgery, anaesthesia, aur robotic instruments ke consumables cover karti hai. Agar saath mein immediate breast reconstruction bhi ki jaati hai — implant ya autologous flap se — toh kharcha aur badhta hai. Zyaadatar major health insurance policies mastectomy cover karti hain; robotic component ke liye TPA se pehle written confirmation lena zaroori hai. Sahyadri Manipal Hospital, Pune mein cashless facility available hai. Detailed cost estimate ke liye hospital ki billing team se contact karein ya Silver Leaf Clinic, Hadapsar par +91 84118 08284 pe call karein.

Q96: What is robotic thyroidectomy (scarless thyroid surgery)?

Ans: Robotic thyroidectomy is the minimally invasive removal of the thyroid gland through a small access incision hidden either in the axilla (armpit) or behind the ear — leaving absolutely no visible scar on the neck. Using the robotic system's three-dimensional magnified view and articulated instruments, the surgeon dissects through the subcutaneous plane from the remote access site to the thyroid gland in the neck, removing it completely without any neck incision. This is in striking contrast to conventional open thyroidectomy, which requires a 5 to 8cm transverse incision across the neck — often leaving a permanently visible scar. Robotic thyroidectomy is an oncologically sound and cosmetically superior alternative for carefully selected patients with thyroid cancer or large benign goitre, and is performed at Sahyadri Manipal Hospital, Pune by Dr. Vinod Gore.

Q97: Is scarless thyroid surgery available in Pune?

Ans: Yes. Robotic scarless thyroidectomy — via the transaxillary or retroauricular approach — is available in Pune at Sahyadri Manipal Hospital, where Dr. Vinod Gore performs robotic thyroid and endocrine surgery as part of a comprehensive robotic oncosurgery programme designated as a Robotic Surgery Centre of Excellence. Dr. Gore holds the Fellowship in Advanced Robotic and Innovative Surgery (FARIS) from the University of Edinburgh — a recognised international qualification in robotic surgical technique — and has extensive experience in head, neck, and endocrine oncosurgery, having trained at Tata Memorial Hospital, Mumbai. Patients considering robotic scarless thyroid surgery can consult at Silver Leaf Clinic, 511 City Centre, Solapur Road, Hadapsar, Pune 411028, or contact +91 84118 08284.

Q98: What is the RABIT (Robotic-Assisted Retroauricular) thyroidectomy procedure?

Ans: RABIT — Robotic-Assisted Bilateral-Axillo-Breast and Retroauricular approach Thyroidectomy — specifically refers to robotic thyroid surgery performed through a small incision hidden behind the ear, in the hairline of the retroauricular area. This access allows the robotic instruments to be tunnelled subcutaneously toward the neck and thyroid without any visible neck incision. The retroauricular approach offers the advantage of an incision that is completely concealed within the natural contour of the ear and scalp — making it the preferred option for patients with a tendency toward hypertrophic scarring or keloid formation, those who wear their hair short, and those with strong aesthetic concerns about any visible neck or axillary scar. The oncological completeness of thyroid removal is equivalent to open thyroidectomy in experienced hands.

Q99: What is the transaxillary robotic thyroidectomy approach?

Ans: Transaxillary robotic thyroidectomy uses a small incision — typically 5 to 6cm — placed in the axilla (armpit), concealed within the natural skin fold. Through this hidden access, a working space is created by dissecting subcutaneously from the axilla across the anterior chest wall to the thyroid gland in the neck. Robotic instruments and camera are then inserted through this access tunnel to perform the thyroidectomy under magnified three-dimensional visualisation, with complete preservation of the anterior neck skin and the absence of any neck incision. The transaxillary approach is most suitable for patients with moderate-sized thyroid glands, normal BMI, and early-stage thyroid cancers not requiring extensive central or lateral neck dissection. It is the most widely adopted robotic thyroidectomy approach globally.

Q100: Will I have any scar on my neck after robotic thyroidectomy?

Ans: No. Robotic thyroidectomy — whether performed via the transaxillary or retroauricular approach — leaves no visible scar on the neck. This is the defining cosmetic advantage of robotic thyroid surgery over conventional open thyroidectomy. The only incision is a small one hidden in the armpit or behind the ear — areas that are easily concealed in everyday clothing and professional attire. For many patients — particularly young women, professionals who work in public-facing roles, performers, teachers, and those with a personal or cultural aversion to visible neck scars — this advantage is profound. It enables patients to undergo necessary thyroid cancer surgery without the permanent visible reminder of the operation that a conventional neck incision leaves. The oncological completeness of thyroid tissue removal is equivalent to open surgery in appropriately selected patients.

Q101: Is scarless thyroidectomy safe for thyroid cancer?

Ans: Yes. Published studies from high-volume robotic thyroid surgery centres — primarily in South Korea, where robotic thyroidectomy was pioneered and has been performed on the largest scale globally — confirm that robotic transaxillary thyroidectomy achieves equivalent oncological outcomes to open thyroidectomy for papillary thyroid cancer, which is the most common thyroid malignancy. Key oncological measures — including completeness of thyroid gland removal, quality of central neck lymph node dissection, post-operative thyroglobulin levels, and long-term recurrence rates — are comparable between robotic and open approaches in carefully selected patients. Patient selection is critical: robotic thyroidectomy is most appropriate for tumours below 4cm without extrathyroidal extension and without bulky lateral neck node involvement requiring extensive lateral neck dissection.

Q102: Who is a good candidate for robotic scarless thyroid surgery?

Ans: The ideal candidate for robotic scarless thyroidectomy is a patient with a single-lobed or bilateral thyroid gland of moderate size — generally below 10cm in the largest dimension — a normal BMI, early-stage papillary thyroid cancer (T1 or T2, N0 or N1a) or a symptomatic benign thyroid nodule (toxic adenoma, follicular neoplasm), and a significant cosmetic concern about a visible neck scar. Patients with very large multinodular goitre extending into the chest (retrosternal goitre), or with bulky lateral neck lymph node metastases requiring formal lateral neck dissection, are generally better managed by open surgery where access and visualisation are less constrained. Patients who have had prior neck surgery may also be less suitable candidates. Your surgeon will review ultrasound, FNAC, and CT findings before confirming suitability.

Q103: Can robotic thyroidectomy treat papillary thyroid cancer?

Ans: Yes. Robotic thyroidectomy is oncologically appropriate and well-validated for papillary thyroid cancer in carefully selected patients. Papillary thyroid cancer is the most common thyroid malignancy and is also one of the most curable human cancers when diagnosed and treated early. The critical surgical requirements — complete removal of the thyroid lobe or entire gland, and clearance of the central compartment lymph nodes (paratracheal and prelaryngeal, Level VI) when indicated — can all be achieved robotically in appropriate cases. Published data from experienced Korean and Indian centres confirm equivalent thyroglobulin levels (a marker of residual thyroid tissue), equivalent recurrence rates, and equivalent central neck lymph node retrieval between robotic and open thyroidectomy for early papillary thyroid cancer.

Q104: Is robotic thyroidectomy covered by health insurance in India?

Ans: Thyroidectomy for thyroid cancer or symptomatic benign goitre is covered by all standard health insurance policies in India. The robotic component — specifically the cost of single-use robotic instruments (consumables) — may or may not be fully reimbursed depending on your individual policy. Many insurers reimburse robotic surgery within an overall procedure package; others have a specific sub-limit for robotic consumables that caps reimbursement. It is strongly recommended to contact your TPA or insurance provider directly before scheduling robotic thyroidectomy, to obtain a written pre-authorisation that specifies whether the robotic approach and its associated consumable costs are included in the approved amount. The insurance desk at Sahyadri Manipal Hospital, Pune can assist with the pre-authorisation process.

Q105: What is the cost of scarless robotic thyroid surgery in India?

Ans: Robotic thyroidectomy — scarless thyroid surgery via the transaxillary or retroauricular approach — costs approximately Rs 1.5 lakhs to Rs 3.5 lakhs in India, depending on the hospital, extent of surgery (hemithyroidectomy versus total thyroidectomy), and whether central neck lymph node dissection is also required. This cost is higher than conventional open thyroidectomy (approximately Rs 60,000 to Rs 1.2 lakhs) primarily because of the additional robotic consumable costs. For patients who prioritise a scar-free outcome — particularly young women, professionals, and those with keloid tendency — this additional cost is frequently considered worthwhile. At Sahyadri Manipal Hospital, Pune, the billing team will provide a detailed cost estimate, and the insurance desk will assist with TPA pre-authorisation to maximise reimbursement.

Q106: How long does robotic thyroidectomy take compared to open surgery?

Ans: Robotic thyroidectomy typically takes 2 to 4 hours, compared to 1 to 2 hours for conventional open thyroidectomy for the same extent of thyroid removal. The additional operative time reflects the setup of the robotic system, the creation of the subcutaneous working space from the axilla or retroauricular approach, and the greater distance the instruments travel to reach the thyroid. With increasing surgeon experience, operating times shorten considerably. At high-volume robotic thyroid surgery centres in Korea, experienced surgeons routinely complete robotic hemithyroidectomy in 90 to 120 minutes. This modest additional operating time is a reasonable trade-off for patients who benefit greatly from the cosmetic advantage of no visible neck scar and the functional advantage of less muscle disruption in the neck.

Q107: Will my voice be affected after robotic thyroidectomy?

Ans: Voice changes after thyroidectomy — whether robotic or open — can occur if the recurrent laryngeal nerve (RLN), which controls the vocal cord on the same side, is temporarily or permanently affected during surgery. Temporary RLN paresis causes a hoarse voice for 6 to 12 weeks while the nerve recovers; permanent RLN injury causes lasting hoarseness and may require voice rehabilitation procedures. The robotic approach's magnified three-dimensional view allows excellent visualisation of the recurrent laryngeal nerve throughout the dissection — potentially reducing the risk of inadvertent nerve injury compared to open thyroidectomy in experienced hands. Intraoperative nerve monitoring (IONM) is used routinely during thyroidectomy at Sahyadri Manipal Hospital to provide real-time feedback on nerve function throughout the operation.

Q108: Can the recurrent laryngeal nerve be preserved better with robotic surgery?

Ans: The magnified three-dimensional view provided by the robotic system offers a potential advantage in the identification and preservation of the recurrent laryngeal nerve (RLN) during thyroidectomy. The RLN runs close to the thyroid gland's posteromedial surface and must be meticulously identified and protected throughout the dissection. Robotic surgery's superior visualisation — up to 10-times magnification — allows the surgeon to clearly see the nerve and its relationship to the inferior thyroid artery, Berry's ligament, and the thyroid parenchyma. Additionally, ICG fluorescence technology is available in robotic programmes to assist with real-time nerve identification. Intraoperative neuromonitoring (IONM) is also used routinely to confirm nerve integrity before, during, and after thyroid resection. Published data suggests equivalent or lower RLN injury rates with robotic compared to open thyroidectomy in experienced centres.

Q109: Is robotic surgery available for parathyroid and adrenal tumours?

Ans: Yes. Robotic surgery is performed for both parathyroid and adrenal tumours at Sahyadri Manipal Hospital, Pune. Robotic parathyroidectomy is offered for primary hyperparathyroidism caused by a single parathyroid adenoma — guided by pre-operative sestamibi scanning and ultrasound to localise the abnormal gland. Robotic adrenalectomy is performed for functional adrenal tumours — phaeochromocytoma, Conn's tumour (aldosteronoma), and Cushing's syndrome — as well as incidentally discovered adrenal masses and adrenal metastases from other primary cancers. Dr. Vinod Gore performs robotic endocrine surgery as part of his comprehensive robotic oncosurgery programme, bringing his Tata Memorial Hospital training and FARIS Edinburgh fellowship expertise to these technically demanding endocrine procedures.

Q110: What is robotic adrenalectomy and who needs it?

Ans: Robotic adrenalectomy is the minimally invasive robotic removal of one or both adrenal glands for a range of clinical conditions. It is most commonly performed for phaeochromocytoma — a tumour that secretes adrenaline and noradrenaline, causing severe hypertension, palpitations, and sweating — where the robotic approach's precision and reduced tissue manipulation are particularly valuable in minimising dangerous intraoperative blood pressure surges. Other indications include Conn's tumour (primary aldosteronism), Cushing's syndrome from adrenal adenoma, adrenocortical carcinoma (ACC), and adrenal metastases from lung, colon, or breast primary cancers. Robotic adrenalectomy achieves equivalent tumour control to open adrenalectomy with significantly reduced blood loss, shorter hospital stay, and faster recovery — important advantages for patients who are already physiologically compromised by the hormonal effects of their adrenal tumour.

Q111: What is robotic prostatectomy (robotic radical prostatectomy)?

Ans: Robotic radical prostatectomy (RARP) is the minimally invasive removal of the entire prostate gland, seminal vesicles, and pelvic lymph nodes through 5 to 6 small abdominal port incisions for the treatment of localised prostate cancer. It is now the most commonly performed cancer operation using the robotic platform worldwide, with over 3 million procedures completed globally. The robotic system's magnified three-dimensional view and wristed instrument movement are particularly advantageous in the confined retropubic space — enabling precise dissection of the prostate from the urethra and rectum below, the bladder above, and the delicate neurovascular bundles that govern urinary and sexual function on either side. At Sahyadri Manipal Hospital, Pune, robotic prostatectomy is performed by Dr. Vinod Gore as part of a comprehensive robotic uro-oncology programme.

Q112: Is robotic prostate surgery available in Pune?

Ans: Yes. Robotic radical prostatectomy for prostate cancer is available at Sahyadri Manipal Hospital, Pune. Dr. Vinod Gore, Department Head Surgical Oncology, holds the FARIS fellowship from the University of Edinburgh and leads a Robotic Surgery Centre of Excellence — a designation awarded by the Robotic Surgeons Association to high-volume robotic programmes demonstrating consistent excellence in oncological outcomes and safety. His comprehensive robotic uro-oncology programme covers prostate, kidney, bladder, and penile cancers, with an integrated approach to pre-operative staging, nerve-sparing surgical technique, and post-operative continence rehabilitation. Consultations are available at Silver Leaf Clinic, 511 City Centre, Solapur Road, Hadapsar, Pune 411028, and at Sahyadri Manipal Hospital.

Q113: How is robotic prostatectomy different from open prostate surgery?

Ans: Open radical prostatectomy (retropubic approach) requires a lower midline incision from the umbilicus to the pubic bone — approximately 15 to 20cm — providing direct access to the prostate in the deep pelvis. Robotic radical prostatectomy (RARP) replaces this with 5 small port incisions, the largest of which is typically 12mm. The advantages of RARP over open prostatectomy are well-established and include significantly reduced intraoperative blood loss — transfusion is rarely required — shorter catheter duration, faster return of urinary continence, better opportunity for bilateral nerve preservation due to superior visualisation of the neurovascular bundles, shorter hospital stay, and faster overall recovery. These advantages do not come at the cost of cancer control — PSA recurrence rates are equivalent between open and robotic prostatectomy in published comparative studies.

Q114: What is the success rate of robotic prostatectomy in India?

Ans: At experienced robotic prostatectomy centres in India, cancer control outcomes are equivalent to internationally published benchmarks. For organ-confined prostate cancer (Stage T2 or less), biochemical recurrence-free survival rates — measured by post-operative PSA remaining undetectable — are in the range of 85 to 95 percent at 5 years. For locally advanced disease (Stage T3), rates are lower and depend on margin status, seminal vesicle involvement, and the use of adjuvant or salvage radiation therapy. Functional outcomes — urinary continence and erectile function recovery — are comparable to, or better than, open prostatectomy in experienced robotic hands. At Sahyadri Manipal Hospital, Pune, Dr. Vinod Gore's programme maintains outcomes data that is regularly reviewed against published national and international benchmarks.

Q115: Will I have urinary incontinence after robotic prostate cancer surgery?

Ans: Temporary urinary incontinence — leakage of urine, particularly with coughing, sneezing, standing, or exertion — is almost universal in the immediate weeks after prostatectomy, both open and robotic, because the urethral sphincter needs time to strengthen and compensate for the change in the pelvic anatomy after prostate removal. With robotic nerve-sparing technique, continence typically recovers faster than after open surgery. In experienced hands, 70 to 85 percent of patients achieve social continence — defined as no pad use or one safety pad daily — within 3 months, and 90 to 95 percent within 12 months. Pre-operative pelvic floor physiotherapy (Kegel exercises) begun at least 4 weeks before surgery significantly accelerates recovery. Post-operative pelvic floor rehabilitation with a specialist physiotherapist is an important part of the recovery programme.

Q116: Can robotic prostatectomy preserve erectile function (nerve-sparing surgery)?

Ans: Yes. Nerve-sparing robotic radical prostatectomy aims to preserve one or both of the neurovascular bundles (NVBs) — delicate structures running alongside the prostate on both sides that carry the cavernous nerves responsible for erectile function. The robotic system's magnified three-dimensional view, tremor filtration, and wristed instruments make the nerve-sparing dissection more precise than open surgery. Bilateral nerve-sparing — preserving both NVBs — is possible when the cancer is confined to the prostate and not extending into the NVBs on pre-operative MRI or intraoperative assessment. Recovery of erections after nerve-sparing prostatectomy is a gradual process taking 6 to 24 months. Patient age, pre-operative erectile function, and whether bilateral or unilateral nerve-sparing was achieved are the key determinants of erectile function recovery.

Q117: How long until urinary control returns after robotic prostatectomy?

Ans: Urinary control returns gradually after catheter removal — which is typically on Day 7 to 10 after robotic prostatectomy. In the first days after the catheter is removed, most patients experience leakage — particularly with activity, coughing, or standing. This improves week by week as the sphincter muscle strengthens and the bladder adapts to the absence of the prostate. Daytime continence typically returns in the majority of patients within 6 to 12 weeks. Night-time continence follows and is usually achieved by 3 to 6 months. Pelvic floor exercises — practised rigorously in the pre-operative period and continued after catheter removal — are the single most important patient-controlled factor in the speed of continence recovery. Pad usage should be tracked and reported at each follow-up visit to monitor progress.

Q118: What is the cost of robotic prostatectomy in India?

Ans: Robotic radical prostatectomy in India costs approximately Rs 3.5 lakhs to Rs 6.5 lakhs, depending on the hospital, city, the extent of pelvic lymph node dissection, and whether bilateral nerve-sparing is performed. This estimate includes the surgical procedure, anaesthesia, robotic instrument consumables, post-operative catheter management, ICU or high-dependency monitoring (usually not required unless there is a co-morbidity), ward accommodation, and standard medications. At Sahyadri Manipal Hospital, Pune, a detailed itemised pre-admission estimate is available from the billing team. Most comprehensive health insurance policies cover robotic prostatectomy — TPA pre-authorisation should be obtained before admission. CGHS, ECHS, and MJPJAY coverage is available for eligible patients.

Q119: Robotic prostatectomy vs radiation therapy — which is better for prostate cancer?

Ans: Both robotic radical prostatectomy and definitive radiation therapy — external beam radiotherapy (EBRT) with or without brachytherapy — are recognised and equivalent treatment options for localised prostate cancer, and no single modality has been conclusively shown to be superior in terms of long-term cancer survival. The ProtecT randomised trial demonstrated comparable prostate cancer-specific mortality between active monitoring, surgery, and radiotherapy at 10 years. The choice between robotic surgery and radiation depends on multiple factors: patient age and life expectancy, PSA level and Gleason grade, cancer stage, prostate volume, preference for a definitive tissue diagnosis (histopathology of the removed prostate), side effect profile preference, and co-morbidities. A thorough discussion with both your surgical oncologist and radiation oncologist is essential before making this important treatment decision.

Q120: How long is the catheter kept after robotic prostatectomy?

Ans: A urinary catheter is placed at the end of robotic prostatectomy to drain the bladder while the urethral anastomosis — the join between the bladder neck and urethra — heals. The catheter is typically kept in place for 7 to 10 days after robotic prostatectomy. In some cases, a cystogram — an X-ray taken with contrast injected through the catheter — is performed just before removal to confirm that the anastomosis has healed without a urine leak. Catheter care instructions are provided before discharge; the catheter is managed at home by the patient or a family member for the days before return to clinic for removal. After catheter removal, incontinence pads are used until urinary control returns — typically within 4 to 12 weeks with pelvic floor exercises.

Q121: What is robotic partial nephrectomy for kidney cancer?

Ans: Robotic partial nephrectomy is the minimally invasive removal of only the tumour-bearing portion of the kidney — together with a margin of surrounding normal kidney tissue — while preserving the remaining functional kidney parenchyma. It is the preferred surgical approach for kidney tumours measuring 7cm or less (Stage T1), and the surgical gold standard for small tumours measuring 4cm or less (Stage T1a). The robotic system's magnified three-dimensional view and articulated instruments allow precise tumour excision within a strictly controlled warm ischaemia time — during which the renal artery is clamped to reduce bleeding — minimising the functional damage to the remaining kidney. Preserving functional kidney tissue is critically important for long-term kidney health and reduces the future risk of chronic kidney disease, cardiovascular complications, and the need for dialysis.

Q122: Can robotic surgery save my kidney in kidney cancer (nephron-sparing)?

Ans: Yes. Robotic partial nephrectomy is specifically designed to save the kidney by removing only the cancer while preserving as much healthy kidney tissue as possible — a principle called nephron-sparing. Multiple large randomised and observational studies have demonstrated that partial nephrectomy achieves equivalent cancer control to radical nephrectomy (full kidney removal) for T1 tumours, while offering significantly better long-term preservation of overall kidney function (GFR — glomerular filtration rate). The clinical implications of preserved kidney function are substantial: reduced risk of hypertension, reduced cardiovascular risk, lower likelihood of requiring haemodialysis in later life, and potentially improved overall long-term survival. Robotic partial nephrectomy is technically demanding — particularly for tumours with a high nephrometry score (complex, deep, or hilar location) — and is best performed at experienced robotic uro-oncology centres.

Q123: What is robotic radical nephrectomy and when is it needed?

Ans: Robotic radical nephrectomy is the complete removal of the kidney — together with the surrounding Gerota's fascia, perinephric fat, and typically the adrenal gland when involved — for kidney cancers that are too large, too centrally placed, or too vascular for safe partial nephrectomy. It is indicated for Stage T2 tumours (7cm or larger), Stage T3 tumours with renal vein or IVC involvement, or any tumour where nephron-sparing is technically not achievable while maintaining an adequate oncological margin. The robotic approach to radical nephrectomy — using 4 to 5 small port incisions — achieves equivalent cancer control to open radical nephrectomy with reduced blood loss, shorter hospital stay of 2 to 3 days, and significantly faster functional recovery compared to the open flank or midline approach.

Q124: Is robotic surgery good for small renal masses (T1 tumours)?

Ans: Robotic partial nephrectomy is the oncological gold standard for T1 renal masses — kidney tumours measuring 7cm or less in diameter. For T1a tumours (4cm or less), nephron-sparing partial nephrectomy is strongly preferred over radical nephrectomy by all major urological oncology guidelines — including EAU and AUA guidelines — because cancer control is equivalent while kidney function is significantly better preserved. The robotic approach makes partial nephrectomy technically more accessible for a broader range of tumour locations and complexities — including posterior, hilar, and endophytic tumours — that might require open surgery when performed laparoscopically. The warm ischaemia time during robotic partial nephrectomy is minimised by experienced surgeons, protecting the remaining kidney from ischaemic damage and optimising post-operative GFR recovery.

Q125: What is robotic radical cystectomy for bladder cancer?

Ans: Robotic radical cystectomy is the minimally invasive removal of the urinary bladder for muscle-invasive bladder cancer (T2 and above) or high-grade non-muscle-invasive bladder cancer (T1 high grade, CIS) that has failed intravesical BCG therapy. In men, the operation also removes the prostate and seminal vesicles; in women, the uterus, cervix, and anterior vaginal wall may also be removed depending on tumour involvement. A pelvic lymph node dissection is performed simultaneously for staging. Following cystectomy, a urinary diversion is created — the most common types are an ileal conduit (urostomy) or an orthotopic neobladder. The robotic approach reduces blood loss significantly, enables faster recovery of bowel function, and shortens hospital stay compared to open radical cystectomy.

Q126: Can a robotic neobladder be created after bladder removal?

Ans: Yes. Orthotopic neobladder reconstruction — creating a new, low-pressure bladder reservoir from a 50 to 60cm segment of ileum that is connected to the urethra — can be performed robotically following robotic cystectomy. This allows the patient to urinate naturally through the urethra, avoiding an external stoma bag. However, not all patients are candidates for neobladder reconstruction: the urethra must be free of tumour involvement, the patient must have adequate renal function, good motivation for post-operative voiding training, and the ability to perform intermittent self-catheterisation if required. Neobladder continence — particularly night-time continence — takes 6 to 12 months to establish fully. A dedicated multidisciplinary team including uro-oncologist, clinical nurse specialist, and continence physiotherapist supports neobladder patients through recovery.

Q127: What is robotic ileal conduit and when is it done?

Ans: Robotic ileal conduit is the creation of a urinary diversion using an isolated segment of ileum — typically 15 to 20cm — after robotic cystectomy, where urine from the ureters drains through this intestinal segment out to a small stoma (opening) on the lower abdominal wall, collected in an external urostomy appliance (bag). The ileal conduit is simpler to construct than a neobladder, has a lower complication rate, and is appropriate for patients who are not suitable for neobladder reconstruction — including elderly patients, those with renal impairment, those with compromised urethral margins, or those who prefer a simpler and more reliable diversion. Stoma care education — provided by a stoma care nurse specialist — is an integral part of preparation and recovery for ileal conduit patients at Sahyadri Manipal Hospital.

Q128: What is robotic retroperitoneal lymph node dissection (RPLND)?

Ans: Robotic retroperitoneal lymph node dissection (RPLND) is the removal of lymph nodes from the retroperitoneal space — the area around the aorta and inferior vena cava between the kidneys and the pelvis — for testicular cancer. It is performed for Stage I non-seminomatous germ cell tumours (NSGCTs) where active surveillance has been chosen over adjuvant chemotherapy, for Stage II disease where residual nodes persist after chemotherapy, or for residual retroperitoneal masses after platinum-based chemotherapy for advanced disease. The robotic approach offers a specific functional advantage over open RPLND: the superior visualisation and precision of the robotic system allow better identification and preservation of the sympathetic nerve chains that govern antegrade ejaculation — significantly reducing the risk of retrograde ejaculation which affects fertility.

Q129: Can robotic surgery be used for testicular cancer lymph node dissection?

Ans: Yes. Robotic RPLND is an established and increasingly preferred approach for retroperitoneal lymph node dissection in carefully selected testicular cancer patients. Suitable candidates include Stage I NSGCT patients choosing primary RPLND over surveillance or adjuvant chemotherapy, and those with residual small retroperitoneal masses after chemotherapy where the pathology (teratoma versus necrosis versus viable GCT) needs to be determined surgically. For post-chemotherapy RPLND with large or complex residual masses, open surgery typically provides better access and is the standard approach. Robotic RPLND offers equivalent nodal clearance to open RPLND with reduced blood loss, no large midline laparotomy incision, shorter hospital stay, and — critically — better nerve-sparing with higher rates of preserved antegrade ejaculation and fertility.

Q130: What is robotic inguinal / groin node dissection (VEIL) for penile cancer?

Ans: VEIL — Video Endoscopic Inguinal Lymphadenectomy — is a robotic-assisted minimally invasive approach to inguinal (groin) lymph node dissection for penile cancer. Conventional open inguinal lymphadenectomy for penile cancer is associated with very high rates of wound complications — wound breakdown, infection, lymphocele, and chronic leg lymphoedema — occurring in up to 50 percent of patients due to the poor skin vascularity in the groin and the extensive dissection required. VEIL — performed through 3 small leg port incisions — achieves equivalent nodal clearance to open dissection while dramatically reducing wound complications and lymphoedema rates. This is a significant advance in penile cancer surgery, where bilateral inguinal node dissection is frequently required and the wound morbidity of open surgery often delays or prevents adequate oncological treatment.

Q131: Does robotic groin node dissection reduce lymphoedema risk?

Ans: Yes. Robotic VEIL for penile cancer significantly reduces the risk of lower limb lymphoedema — chronic swelling of one or both legs due to disruption of lymphatic drainage — compared to conventional open inguinal lymphadenectomy. The minimally invasive endoscopic approach preserves a larger proportion of the lymphatic channels in the groin, reduces the formation of lymphocele (lymphatic fluid collections), and avoids the extensive skin and subcutaneous tissue damage of open groin dissection. Published comparative studies confirm that the rate of significant lymphoedema after VEIL is substantially lower than after open dissection — a critical quality-of-life outcome for patients with penile cancer who are often young or middle-aged men for whom chronic leg swelling would significantly impair work and activity.

Q132: Is robotic surgery available for ureteric cancer (nephroureterectomy)?

Ans: Yes. Robotic nephroureterectomy — removal of the kidney and the entire length of the ureter, including the ureteric orifice and a cuff of bladder, for urothelial carcinoma of the upper urinary tract (renal pelvis and ureter) — is performed at Sahyadri Manipal Hospital, Pune. Upper tract urothelial carcinoma (UTUC) requires removal of the entire ureter to prevent stump recurrence — a risk unique to this cancer type. The robotic approach facilitates complete dissection of the ureter through the pelvis to the bladder, including precise excision of the ureteric orifice, without the need for a separate second incision or intraoperative repositioning that is often required for open or laparoscopic nephroureterectomy. Pelvic lymph node dissection is also performed robotically in the same setting for staging purposes.

Q133: What is the recovery time after robotic kidney cancer surgery?

Ans: Recovery after robotic kidney cancer surgery is significantly faster than after open kidney surgery. After robotic partial nephrectomy, patients are typically discharged within 2 to 4 days and return to light daily activities within 2 to 3 weeks, with full recovery including return to work and physical exercise within 4 to 6 weeks. After robotic radical nephrectomy, hospital stay is 2 to 3 days and full recovery typically takes 3 to 4 weeks. These recovery times compare to 7 to 10 days in hospital and 8 to 12 weeks for full recovery after open kidney surgery. Specific restrictions after partial nephrectomy include avoidance of heavy lifting and strenuous physical activity for 4 to 6 weeks to protect the reconstructed kidney surface from haemorrhage.

Q134: Will I need dialysis after robotic kidney cancer surgery?

Ans: The need for dialysis after kidney cancer surgery depends on the functional status of the remaining kidney or kidney tissue, not the surgical approach itself. After robotic partial nephrectomy — where the tumour is removed and the remaining kidney is preserved — dialysis is not required in the vast majority of patients, provided the other kidney was functioning normally before surgery. After robotic radical nephrectomy — where the entire kidney is removed — patients rely entirely on the remaining contralateral kidney. If the remaining kidney has normal function, a single kidney is entirely sufficient for life without dialysis. Dialysis is only needed if the remaining kidney was already significantly compromised by diabetes, hypertension, pre-existing kidney disease, or if both kidneys required surgery. Pre-operative kidney function is carefully assessed before planning the surgical approach.

Q135: Prostate cancer ki robotic surgery ke baad sex life normal hoti hai?

Ans: Prostate cancer ki robotic surgery — nerve-sparing radical prostatectomy — ke baad sex life ki wapsi ek gradual aur patient-specific process hoti hai. Surgery mein prostate ke bagal mein ek ya dono neurovascular bundles — jo erection ke liye responsible nerves hain — ko preserve karne ki koshish ki jaati hai. Erection ki recovery mein 6 mahine se 2 saal tak ka time lag sakta hai. Recovery ki sambhavna in cheezon pe depend karti hai: age (40 saal zyada sambhavna, 70 saal kam), surgery se pehle erectile function kaisi thi, aur bilateral ya sirf unilateral nerve-sparing ki gayi. Sahyadri Manipal Hospital mein Dr. Vinod Gore ke saath pre-operative discussion mein aapki personal expectations aur nerve-sparing ki feasibility clearly discuss ki jaati hai.

Q136: What is a robotic radical hysterectomy?

Ans: Robotic radical hysterectomy is the minimally invasive removal of the uterus, cervix, upper third of the vagina, parametrial tissues, and pelvic lymph nodes for the treatment of early-stage cervical cancer. It is the surgical standard of care for Stage IA2 and small Stage IB1 cervical cancers. The robotic approach provides a magnified three-dimensional view within the confined pelvis — facilitating precise dissection of the ureters, uterine vessels, paracervical tissue, and the autonomic nerves that control bladder and bowel function. Preservation of the pelvic nerve plexus during robotic radical hysterectomy has been shown to improve post-operative bladder function recovery compared to open radical hysterectomy, significantly improving quality of life for patients treated for early cervical cancer.

Q137: Is robotic hysterectomy safe for cervical cancer in India?

Ans: Robotic radical hysterectomy for cervical cancer is performed at experienced gynaecological oncology centres in India and can be safe and oncologically effective when applied with strict patient selection criteria — particularly following the findings of the LACC (Laparoscopic Approach to Cervical Cancer) trial published in 2018. The LACC trial significantly changed surgical practice by demonstrating inferior outcomes for minimally invasive approaches compared to open surgery in an unselected population. Consequently, robotic radical hysterectomy should now only be offered to carefully selected patients — typically those with small tumours measuring 2cm or less, no lymphovascular space invasion on pre-operative biopsy, and utilising specific technical precautions to prevent tumour cell spillage during minimally invasive extraction. A thorough pre-operative discussion with your surgical oncologist is essential.

Q138: What does the LACC trial say about robotic surgery for cervical cancer?

Ans: The LACC (Laparoscopic Approach to Cervical Cancer) trial, published in the New England Journal of Medicine in 2018, was a landmark randomised controlled trial that compared minimally invasive radical hysterectomy — including laparoscopic and robotic approaches — with open radical hysterectomy for early-stage cervical cancer. The trial found that minimally invasive surgery was associated with significantly lower disease-free survival (3-year DFS: 91.2 percent versus 97.1 percent for open surgery) and higher rates of tumour recurrence. These findings led to a major change in global surgical practice: minimally invasive radical hysterectomy for cervical cancer is now performed only in highly selected patients with strict attention to tumour characteristics and surgical technique aimed at preventing intraoperative tumour dissemination.

Q139: Is robotic radical hysterectomy still recommended for early-stage cervical cancer?

Ans: Following the LACC trial, robotic radical hysterectomy for cervical cancer is no longer universally recommended for all patients with early-stage disease. It remains a surgical option — at experienced centres — for a highly selected subgroup of patients: specifically those with tumours measuring 2cm or less, no lymphovascular space invasion on pre-operative biopsy, squamous or adenosquamous histology, and tumours confirmed by experienced gynaecological oncologists to be at low risk of intraoperative dissemination. Specific surgical techniques — including avoiding uterine manipulators, using a vaginal closure technique before uterine division, and contained specimen removal — are applied to mitigate dissemination risk. Open radical hysterectomy remains the standard for most cervical cancer patients who are surgical candidates.

Q140: What is robotic surgery for endometrial / uterine cancer?

Ans: Robotic total hysterectomy with bilateral salpingo-oophorectomy (removal of both fallopian tubes and ovaries) and pelvic lymphadenectomy is the standard minimally invasive surgical treatment for endometrial (uterine) cancer — which is the most common gynaecological malignancy in India and globally. The robotic approach is particularly valuable for endometrial cancer because many affected women are obese, elderly, or have significant medical comorbidities — a population in whom the advantages of minimally invasive surgery (reduced blood loss, shorter hospital stay, faster recovery, lower wound infection risk) are especially important. Robotic surgical staging for endometrial cancer — including thorough pelvic and selective para-aortic lymphadenectomy — achieves equivalent nodal harvest and staging accuracy to open surgery in experienced hands.

Q141: Can robotic surgery treat early-stage ovarian cancer?

Ans: Robotic surgery has a defined but limited role in ovarian cancer management. For apparent Stage I ovarian cancer — where pre-operative imaging and surgical findings suggest disease confined to the ovary or ovaries — robotic comprehensive surgical staging is appropriate: total hysterectomy with bilateral salpingo-oophorectomy, pelvic and para-aortic lymphadenectomy, omentectomy, and peritoneal biopsies. Accurate staging determines whether adjuvant chemotherapy is required and can avoid over-treatment of true Stage I disease. For advanced ovarian cancer (Stage III–IV), where primary debulking surgery must aim for complete macroscopic clearance of peritoneal disease, open surgery is the standard approach — robotic access does not permit the same extent of peritoneal and bowel mobilisation that optimal cytoreduction requires.

Q142: What is robotic pelvic lymph node dissection?

Ans: Robotic pelvic lymph node dissection removes the lymph node-bearing tissue from the bilateral obturator fossa and along the external and internal iliac vessels within the pelvis — for cancer staging or therapeutic purposes. It is routinely performed during robotic radical hysterectomy for cervical cancer, robotic hysterectomy for endometrial cancer, and robotic radical prostatectomy for prostate cancer. The robotic system's superior visualisation allows precise identification and preservation of the obturator nerve, genitofemoral nerve, and the lateral wall structures, while thoroughly clearing the lymphatic tissue between the vessels. Adequate pelvic lymph node harvest — typically 15 to 25 nodes per side — is a quality benchmark for gynaecological and prostate cancer surgery and is consistently achievable with the robotic approach.

Q143: What is robotic para-aortic lymphadenectomy?

Ans: Robotic para-aortic lymphadenectomy is the removal of lymph nodes from the retroperitoneal space surrounding the aorta and inferior vena cava — between the level of the renal vessels above and the common iliac vessels below — for comprehensive surgical staging of gynaecological cancers, particularly intermediate and high-risk endometrial cancer and selected cervical cancers. Para-aortic node involvement, if present, upstages the disease and changes the radiation field from pelvic to extended-field (pelvic plus para-aortic) — significantly affecting the patient's treatment plan and prognosis. Robotic para-aortic lymphadenectomy requires precise dissection around major vascular structures and is facilitated by the robotic system's magnified view and articulated instruments, particularly for the upper retroperitoneal dissection below the left renal vein.

Q144: Can the uterus and ovaries be removed together robotically (TLH-BSO)?

Ans: Yes. Robotic total laparoscopic hysterectomy with bilateral salpingo-oophorectomy (TLH-BSO) — removing the uterus, cervix, both fallopian tubes, and both ovaries — is the standard robotic surgical procedure for early endometrial cancer. The procedure is performed through 4 to 5 small abdominal port incisions under robotic guidance. The uterus is divided from its ligamentous supports and blood supply under magnified visualisation, and the vaginal vault is sutured robotically. The specimen is removed vaginally. Comprehensive pelvic lymphadenectomy and selective para-aortic lymphadenectomy are added as part of surgical staging when indicated by tumour risk stratification — based on grade, depth of myometrial invasion, histological subtype, and patient age. Hospital stay is typically 2 to 3 days after robotic TLH-BSO with staging lymphadenectomy.

Q145: How long is recovery after robotic hysterectomy for cancer?

Ans: Recovery after robotic hysterectomy for gynaecological cancer is significantly faster than after open (abdominal) hysterectomy. Hospital stay after robotic hysterectomy with pelvic lymphadenectomy is typically 2 to 3 days — compared to 5 to 7 days after open surgery. Return to light daily activities is usually possible within 1 to 2 weeks. Driving can be resumed within 2 to 3 weeks once pain is adequately managed and reflexes are normal. Full return to normal physical activity and work — including non-strenuous office work — is typically achieved within 4 to 6 weeks of robotic hysterectomy. This compares to 6 to 8 weeks for open hysterectomy. Specific restrictions include avoidance of heavy lifting (more than 5kg) and sexual intercourse for 6 to 8 weeks while the vaginal vault heals.

Q146: What is the cost of robotic hysterectomy in Pune?

Ans: Robotic radical hysterectomy with pelvic lymph node dissection for cervical cancer, or robotic total hysterectomy with bilateral salpingo-oophorectomy and pelvic staging lymphadenectomy for endometrial cancer, in Pune costs approximately Rs 2.5 lakhs to Rs 5 lakhs. The variation reflects the extent of the lymphadenectomy required — pelvic only versus pelvic plus para-aortic — the duration of surgery, the type of hospital accommodation, and any post-operative requirements. Most health insurance policies in India cover hysterectomy for gynaecological cancer — TPA pre-authorisation should be obtained before admission. MJPJAY coverage is available for eligible Maharashtra residents. The hospital's insurance desk at Sahyadri Manipal Hospital provides end-to-end support for the pre-authorisation and cashless admission process.

Q147: Will I have menopausal symptoms after robotic radical hysterectomy?

Ans: Surgical menopause — with immediate onset of menopausal symptoms — occurs when both ovaries are removed during hysterectomy. This is routine in cervical cancer surgery (bilateral oophorectomy is standard), and universal in endometrial and ovarian cancer surgery. Symptoms include hot flushes, night sweats, mood changes, vaginal dryness, reduced libido, disturbed sleep, and a long-term risk of osteoporosis and cardiovascular disease. Hormone replacement therapy (HRT) may be considered to manage menopausal symptoms — its appropriateness depends on the cancer type and stage. HRT is generally safe and beneficial after cervical cancer surgery but requires careful discussion after hormone-sensitive cancers. Bone health monitoring, calcium and Vitamin D supplementation, and regular weight-bearing exercise are important components of long-term post-surgical care.

Q148: Can a young patient preserve fertility with robotic cervical cancer surgery (trachelectomy)?

Ans: Yes. Robotic radical trachelectomy — which removes the cervix and upper vagina while preserving the uterine body, fallopian tubes, and ovaries — is a fertility-preserving surgical option for young women with early cervical cancer who wish to conceive after treatment. It is appropriate for carefully selected patients: typically Stage IA2 or small Stage IB1 cervical cancers with tumours measuring 2cm or less, no involvement of the upper cervix or uterine isthmus, and no adverse prognostic features on MRI and biopsy. A cerclage (permanent suture) is placed at the level of the internal os to provide structural support for future pregnancies. Subsequent pregnancies after radical trachelectomy are possible, though at higher risk of preterm delivery. Robotic trachelectomy is performed at select specialised oncology centres in India.

Q149: Is robotic surgery for endometrial cancer covered by insurance?

Ans: Hysterectomy for endometrial (uterine) cancer — whether performed robotically, laparoscopically, or by open surgery — is covered by all standard comprehensive health insurance policies in India, as it is a medically necessary surgical treatment for a malignant condition. The robotic component — specifically the additional cost of single-use robotic instruments — may be subject to a sub-limit or co-payment clause in some older Mediclaim policies. Newer policies under the IRDAI standardised framework generally cover robotic surgery more comprehensively. It is strongly recommended to contact your TPA or insurer directly before scheduling the operation to obtain a written pre-authorisation specifying the robotic approach. The insurance desk at Sahyadri Manipal Hospital will assist with all documentation and the cashless admission process.

Q150: Bachhedani ka cancer ki robotic surgery kaise hoti hai?

Ans: Bachhedani — yaani uterus — ke cancer, jaise endometrial cancer ya cervical cancer, ki robotic surgery is tarah ki jaati hai: surgeon console par baithkar 4 se 5 chhote chhedon — sirf 8 se 12mm ke — ke zariye robotic haath patient ke pet mein daalta hai. High-definition 3D camera se poori detail dikhti hai. Uterus, cervix, ovaries, aur zaroorat hone par pelvis ke lymph nodes nikale jaate hain — bilkul waisay hi jaise open surgery mein — lekin bina bade chiire ke. Isliye dard bahut kam hota hai, khoon bahut kam nikalta hai, aur hospital mein sirf 2 se 3 din rehna padta hai. Dr. Vinod Gore Sahyadri Manipal Hospital, Pune mein yeh surgery karte hain. Appointment ke liye +91 84118 08284 pe call karein.

Q151: What is ICG (Indocyanine Green) fluorescence-guided surgery?

Ans: Indocyanine Green (ICG) fluorescence-guided surgery is an advanced intraoperative imaging technique that uses a safe green dye — ICG — to make specific anatomical structures and pathological tissues visible in real time during robotic or laparoscopic surgery. When injected intravenously or into tissue around a tumour, ICG is taken up by lymphatic channels, bile ducts, blood vessels, and certain tumour tissues. Under near-infrared light — which the robotic camera system (Firefly on the da Vinci robot) can switch to instantaneously — the ICG-containing structures emit a visible green fluorescent glow against a dark background. This real-time imaging allows the surgeon to identify lymph nodes, assess blood supply to bowel anastomoses, map bile ducts, detect tumour margins, and identify sentinel lymph nodes — all during the live operation, without pausing surgery or changing instruments.

Q152: How does ICG fluorescence imaging work during cancer surgery?

Ans: ICG fluorescence imaging works on the principle of near-infrared (NIR) fluorescence. ICG dye absorbs light at 800nm (near-infrared wavelength) and emits fluorescent light at 820nm, which is captured by a near-infrared-sensitive camera — the Firefly system built into the da Vinci robotic platform. The surgeon can toggle between standard white-light view and near-infrared fluorescence view at the press of a button on the console, without any change in instruments or operative position. Different applications require different ICG dosing and timing: for sentinel node mapping, ICG is injected peritumorally before surgery and imaged as it tracks through lymphatics; for anastomotic perfusion, ICG is given intravenously and imaged as it reaches the bowel within 30 to 60 seconds; for bile duct mapping, ICG given 12 to 24 hours before surgery accumulates in the biliary system.

Q153: Is ICG dye safe for cancer patients?

Ans: Yes. ICG (Indocyanine Green) has an excellent safety record, having been used in medical practice for over 50 years — originally for cardiac output measurement and liver function assessment. It is cleared from the body entirely by the liver via biliary excretion, with complete elimination within 24 hours of administration. Adverse reactions to ICG are extremely rare — the published incidence of significant allergic reactions is less than 1 in 40,000 administrations. The only specific contraindication is allergy to iodine or iodide compounds, as the ICG formulation contains sodium iodide. Patients with significant liver dysfunction may retain ICG longer than normal, but this does not affect safety at the low doses used for fluorescence imaging. ICG requires no special radiation precautions and can be used in pregnant patients when clinically essential.

Q154: What is sentinel lymph node biopsy using ICG?

Ans: Sentinel lymph node (SLN) biopsy using ICG is a technique for identifying the first lymph node or nodes that drain the area of a tumour — the sentinel nodes — which are the most likely first site of lymph node metastasis. ICG is injected around the tumour (peritumorally) or into the subareolar plexus before or at the start of surgery. The dye travels through the lymphatic channels and accumulates in the sentinel lymph node, which then fluoresces green under the robotic camera's near-infrared mode. The glowing sentinel node is surgically removed and sent for immediate frozen section pathological analysis. If the sentinel node is free of cancer cells, the patient is spared a full regional lymph node dissection — avoiding the significant morbidity of lymphoedema, nerve injury, and wound complications associated with formal nodal clearance.

Q155: Why is sentinel lymph node biopsy important in breast cancer?

Ans: Sentinel lymph node biopsy (SLNB) has transformed the management of early breast cancer by allowing accurate assessment of axillary lymph node status without the need for full axillary lymph node dissection in the majority of patients. Axillary lymph node dissection — removal of all Level I and II axillary nodes — carries a significant risk of chronic arm lymphoedema (20 to 30 percent), shoulder stiffness, arm numbness, and wound infection. By identifying the sentinel node and selectively removing only the first draining node or nodes, SLNB avoids these complications in the large proportion of patients whose sentinel node proves cancer-free. ICG-guided SLNB improves sentinel node detection rates to 97 to 99 percent — superior to blue dye alone or technetium radioisotope alone — making ICG the preferred agent for sentinel node mapping in breast cancer at robotic oncosurgery centres.

Q156: Can ICG fluorescence detect sentinel nodes in cervical and endometrial cancer?

Ans: Yes. ICG sentinel lymph node mapping is increasingly used for surgical staging of early-stage cervical and endometrial cancers, replacing or supplementing traditional bilateral systematic pelvic lymphadenectomy. In cervical cancer, ICG is injected into the cervical stroma at the tumour margin at the start of surgery; the dye travels through parametrial lymphatics to the sentinel nodes in the obturator and external iliac regions. In endometrial cancer, ICG is injected into the uterine cervix. Bilateral sentinel node detection rates with ICG are approximately 95 percent — significantly higher than with blue dye alone. When the sentinel nodes are negative, a full systematic pelvic lymphadenectomy may be avoided in low-risk cases, reducing the risk of lower limb lymphoedema and other lymphadenectomy-related complications while maintaining accurate pathological staging.

Q157: Is ICG sentinel node mapping used in melanoma and skin cancer?

Ans: Yes. ICG fluorescence is used for sentinel lymph node mapping in cutaneous melanoma and, increasingly, in Merkel cell carcinoma — the two most common skin cancers for which SLN biopsy is clinically relevant and prognostically important. In melanoma, SLN biopsy guides the decision on completion lymph node dissection and eligibility for adjuvant immunotherapy. Traditional melanoma SLN mapping uses technetium-99m radioisotope injection and a gamma probe — a technique that requires nuclear medicine facilities and radiation safety precautions. ICG fluorescence provides a complementary real-time visual guidance for SLN identification in the operating theatre, improving the surgeon's ability to directly visualise the lymphatic channel leading to the sentinel node — particularly useful for truncal and head-and-neck melanomas where lymphatic drainage can be unpredictable.

Q158: How does ICG help in colorectal cancer surgery — anastomotic perfusion check?

Ans: After the diseased bowel segment is removed and the two healthy bowel ends are joined together (anastomosis) during colorectal surgery, an anastomotic leak — where the join breaks down — is one of the most serious and feared post-operative complications, occurring in approximately 3 to 10 percent of colorectal resections. Inadequate blood supply to the bowel ends at the anastomotic site is a major contributing factor to leaks. ICG fluorescence anastomotic perfusion assessment addresses this directly: after the anastomosis is fashioned, ICG is injected intravenously and reaches the bowel within 30 to 60 seconds. The surgeon switches to fluorescence mode and directly observes whether the bowel at the anastomosis fluoresces brightly (indicating adequate blood supply) or appears dark (indicating poor perfusion and high leak risk). If perfusion is inadequate, the anastomosis can be revised intraoperatively before closing — potentially preventing a catastrophic post-operative complication.

Q159: Can ICG fluorescence reduce anastomotic leaks after rectal cancer surgery?

Ans: Yes. Multiple prospective studies and meta-analyses have demonstrated that ICG perfusion assessment of colorectal anastomoses significantly reduces anastomotic leak rates. A landmark multicentre study found that ICG assessment prompted intraoperative revision of the anastomosis — due to identified poor perfusion — in approximately 8 percent of cases, and that this intervention prevented the majority of those potential leaks from occurring. For low rectal anastomoses — which already carry the highest leak risk due to their depth in the pelvis and limited blood supply — ICG perfusion assessment has become an important safety tool that is now widely adopted at major robotic colorectal surgery centres internationally. At Sahyadri Manipal Hospital, Pune, ICG-guided anastomotic perfusion assessment is routinely used during robotic colorectal cancer surgery as part of a comprehensive intraoperative safety protocol.

Q160: What is real-time tumour margin assessment using ICG?

Ans: Achieving clear surgical margins — complete removal of the cancer with no tumour cells at the cut edge of the specimen — is the fundamental goal of cancer surgery. Residual tumour at the margin (R1 resection) significantly worsens prognosis. ICG fluorescence is used in selected cancer types to assist with real-time intraoperative margin assessment. Certain tumours — particularly hepatocellular carcinoma (HCC), cholangiocarcinoma, colorectal liver metastases, and some ovarian cancers — accumulate ICG due to abnormal hepatic retention or tumour-specific uptake mechanisms. Under fluorescence imaging, these tumour foci glow green against the background liver or tissue — revealing small surface metastases or residual tumour deposits that are invisible to the surgeon's naked eye and to white-light imaging. This technique is particularly valuable during robotic liver resection, where ICG imaging before and during resection can guide the precise extent of liver tissue removal.

Q161: Does ICG fluorescence improve lymph node yield in gastric cancer surgery?

Ans: Yes. ICG-guided fluorescence lymphadenectomy for gastric cancer is an emerging technique that improves the completeness and total number of lymph nodes harvested during D2 gastrectomy — a critical quality metric for gastric cancer surgery that directly affects staging accuracy and potentially survival. ICG is injected endoscopically around the gastric tumour 1 to 2 days before surgery. By the time of surgery, the dye has tracked through the perigastric lymphatics and the fluorescence marks the lymph node-bearing tissue along the gastric vessels — particularly the second-tier D2 nodes — that must be included in a complete D2 lymphadenectomy. Published studies from Japan and Korea confirm that ICG-guided D2 gastrectomy retrieves a greater number of total nodes and a greater number of D2 nodes compared to conventional D2 gastrectomy, with equivalent safety.

Q162: Is ICG fluorescence used during robotic liver resection?

Ans: Yes. ICG fluorescence is one of the most valuable and widely used applications in robotic hepatic surgery. ICG administered intravenously 24 to 72 hours before liver resection accumulates selectively in hepatocellular carcinoma (HCC) and — at lower doses and different timing — in colorectal liver metastases. At the time of surgery, the fluorescence mode of the robotic camera reveals these ICG-retaining tumour deposits on the liver surface as brightly glowing foci, even when they are too small to be felt by palpation (which is not possible in robotic surgery) or when they are not visible under white light. This allows the surgeon to detect previously unseen satellite nodules or small additional metastases — potentially changing the operative plan. ICG also delineates segment boundaries when injected into the portal vein branch of the segment to be resected, guiding precise anatomical hepatectomy.

Q163: How is Firefly fluorescence imaging integrated with da Vinci robot?

Ans: Firefly is the proprietary near-infrared fluorescence imaging system fully integrated into the da Vinci robotic platform by Intuitive Surgical. The Firefly system incorporates a near-infrared-sensitive camera and a 800nm near-infrared illumination source directly into the robotic endoscope — the same scope used for the standard three-dimensional white-light view throughout surgery. The surgeon can switch between standard white-light view and Firefly near-infrared fluorescence view instantaneously by pressing a button on the surgeon console, without any change in camera position, instrument configuration, or operative posture. The fluorescence view is displayed in pseudo-colour (typically with ICG-containing structures shown in green against a dark background) and can be overlaid with the white-light image in a picture-in-picture format, allowing simultaneous anatomical orientation and fluorescence guidance during complex dissection.

Q164: Is ICG-guided surgery available in Pune?

Ans: Yes. ICG fluorescence-guided robotic surgery is available at Sahyadri Manipal Hospital, Pune, as part of Dr. Vinod Gore's comprehensive robotic oncosurgery programme. The da Vinci robotic system at Sahyadri Manipal is equipped with the Firefly near-infrared fluorescence imaging system. Dr. Gore uses ICG fluorescence for multiple applications across his robotic oncosurgery practice: sentinel lymph node mapping in breast, gastric, and gynaecological cancers; anastomotic perfusion assessment during robotic colorectal cancer surgery; biliary anatomy delineation during HPB procedures; intraoperative margin assessment during robotic liver surgery; and organ perfusion assessment during other complex oncological resections. Patients undergoing robotic cancer surgery at Sahyadri Manipal Hospital can therefore benefit from the full range of ICG-guided intraoperative imaging capabilities as a standard component of their operative care.

Q165: Does ICG fluorescence-guided surgery cost extra?

Ans: The cost implications of ICG fluorescence-guided surgery are modest in the context of the overall cost of robotic oncosurgery. ICG dye itself — Pulsion ICG or equivalent — is relatively inexpensive, typically costing Rs 5,000 to Rs 15,000 per vial depending on the brand and supplier. The Firefly near-infrared fluorescence imaging system is fully integrated into the da Vinci robotic platform and does not require any additional equipment beyond what is already part of the robotic setup — so there is no separate equipment hire or capital cost for ICG-guided imaging. The main cost is the ICG dye itself, which is itemised in the hospital's procedure costing. The investment in ICG-guided surgery is well justified by the clinical benefits — reduced anastomotic leak rates, improved sentinel node detection, and enhanced margin assessment — which can prevent costly and morbid post-operative complications.

Q166: What is the cost of robotic cancer surgery in Pune?

Ans: The cost of robotic cancer surgery in Pune varies significantly by procedure type, complexity, hospital stay duration, and whether ICU care is required. As a general guide: robotic prostatectomy Rs 3.5 to 6.5 lakhs; robotic colectomy or LAR Rs 3 to 6 lakhs; robotic Whipple's Rs 4.5 to 8 lakhs; robotic lobectomy Rs 3.5 to 7 lakhs; robotic mastectomy Rs 2.5 to 5 lakhs; robotic hysterectomy Rs 2.5 to 5 lakhs. These estimates include surgery, anaesthesia, robotic consumables, accommodation, nursing, and standard medications. Pre-operative investigations, pathology, post-operative chemotherapy, radiation therapy, and outpatient follow-up are separate costs. At Sahyadri Manipal Hospital, Pune, the billing team provides a detailed itemised cost estimate before admission. Cashless insurance, MJPJAY, and Ayushman Bharat coverage are available.

Q167: Why is robotic cancer surgery more expensive than open surgery?

Ans: Robotic cancer surgery carries a higher upfront cost than open surgery for several reasons. The da Vinci robotic system is an expensive piece of capital equipment — costing approximately 2 to 3 million US dollars — with significant ongoing maintenance costs that are recovered through procedure fees. Each robotic case also uses single-use sterile instruments (robotic consumables) — including the robotic trocar sleeves, scissors, needle drivers, bipolar forceps, and stapler cartridges — that add Rs 50,000 to Rs 1.5 lakhs per case. Operating time for robotic procedures is generally somewhat longer than open cases, adding anaesthesia and theatre costs. However, when the total episode cost is considered — including shorter hospital stay, lower blood transfusion requirements, fewer wound complications, and faster return to work — the cost differential between robotic and open surgery is significantly narrowed.

Q168: Is robotic surgery covered by health insurance in India?

Ans: Yes, in the vast majority of cases. Robotic surgery for cancer is covered by most comprehensive individual and group health insurance policies in India. The Insurance Regulatory and Development Authority of India (IRDAI) does not permit blanket exclusions of robotic surgery from health insurance policies. However, individual policy documents may contain sub-limits on robotic consumable costs — capping reimbursement at a fixed amount (for example, Rs 50,000 to Rs 1.5 lakhs for consumables) even when the actual consumable cost is higher. It is strongly recommended to read the specific terms of your policy or contact your TPA directly before the surgery to obtain written pre-authorisation and a clear statement of what will be covered under your policy. The insurance desk at Sahyadri Manipal Hospital, Pune provides comprehensive guidance on this process.

Q169: Does IRDAI mandate insurance coverage for robotic surgery?

Ans: The Insurance Regulatory and Development Authority of India (IRDAI) has issued clear guidelines prohibiting the exclusion of modern surgical techniques — including robotic surgery — from health insurance coverage on the grounds that they are new or technology-based treatments. IRDAI's standard health product guidelines and the standardised Arogya Sanjeevani policy include robotic surgery as a covered procedure. However, the IRDAI framework does allow insurers to structure policy terms — including deductibles, co-payment clauses, and sub-limits for consumables — which can result in partial rather than full coverage of robotic surgical costs. Patients should verify the specific terms of their policy annually, particularly when renewing health insurance, to ensure that robotic surgical coverage terms are adequate for their potential needs. IRDAI's consumer helpline (155255) can be consulted for policy-related complaints.

Q170: Are there sub-limits or co-payments for robotic surgery in Indian Mediclaim policies?

Ans: Yes. Many Indian Mediclaim and group health insurance policies contain sub-limits or co-payment clauses specifically applicable to robotic surgery. The most common structure is a sub-limit on robotic consumables — capping the reimbursement for single-use robotic instruments at a fixed amount, such as Rs 1 lakh, regardless of the actual consumable cost incurred. Other policies require a co-payment of 10 to 20 percent of the total robotic procedure cost, with the insured patient bearing this proportion out of pocket. These sub-limits and co-payments are disclosed in the policy schedule or product brochure — patients should read the fine print carefully. When comparing health insurance plans at renewal, robotic surgery consumable coverage is an important criterion to evaluate, particularly for patients at higher risk of cancer or those with a family history of malignancy.

Q171: Is robotic cancer surgery covered under Ayushman Bharat (PMJAY)?

Ans: Ayushman Bharat — Pradhan Mantri Jan Arogya Yojana (PMJAY) — is India's government health insurance scheme for economically weaker sections, providing coverage of up to Rs 5 lakhs per family per year for hospitalisation across a defined list of health benefit packages. Selected cancer surgery procedures — including specific robotic oncology procedures that fall within approved HBP package rates — are covered for eligible PMJAY beneficiaries at empanelled hospitals. The coverage is package-based, meaning a fixed rate is approved per procedure regardless of the actual robotic consumable cost. Sahyadri Manipal Hospital, Pune is empanelled under Ayushman Bharat PMJAY. Patients should bring their Ayushman Bharat card (or e-card accessible via PM-JAY app), Aadhar card, and relevant medical documents for eligibility verification and pre-authorisation at the hospital's dedicated PMJAY desk before admission.

Q172: Which hospitals in Pune are empanelled under Ayushman Bharat for robotic oncology?

Ans: Sahyadri Manipal Hospital, Pune is empanelled under Ayushman Bharat PMJAY for cancer surgery and offers cashless treatment for eligible PMJAY beneficiaries across a range of oncological procedures. Empanelment details — including which specific procedure packages are covered and at what approved rates — are available on the PM-JAY portal (pmjay.gov.in) by searching by hospital name, or by contacting the hospital's insurance desk directly. To use Ayushman Bharat benefits at Sahyadri Manipal Hospital, bring your Ayushman Bharat e-card or golden card (verifiable via your Aadhar-linked mobile number on the PM-JAY app), along with your cancer diagnosis documents, biopsy report, and imaging. The PMJAY beneficiary services desk at the hospital will verify eligibility and assist with pre-authorisation before admission for robotic cancer surgery.

Q173: How do I get TPA pre-authorisation for robotic cancer surgery?

Ans: TPA (Third Party Administrator) pre-authorisation is the process by which your health insurance company formally approves the planned surgical treatment before you are admitted to hospital — enabling cashless hospitalisation. The process works as follows: your surgeon at Sahyadri Manipal Hospital prepares a treatment plan letter specifying the planned robotic procedure, diagnosis, and estimated cost. This is submitted to your TPA along with supporting documents — biopsy report, CT or MRI or PET-CT imaging report, blood tests, and the hospital's pre-admission estimate. Most TPAs process pre-authorisation requests within 24 to 72 hours. Urgent pre-auths for cancer cases are sometimes processed faster on request. Sahyadri Manipal Hospital's insurance desk manages the entire TPA submission process on your behalf, following up until approval is received, and ensuring a smooth cashless admission.

Q174: What documents are needed for cashless robotic surgery in Pune?

Ans: To access cashless robotic cancer surgery at Sahyadri Manipal Hospital, Pune, you will need the following documents: your health insurance card (physical or digital) with current policy number; a government-issued photo ID (Aadhar, PAN, or passport); your surgeon's written treatment plan or referral letter; the biopsy or histopathology report confirming cancer diagnosis; imaging reports (CT scan, MRI, PET-CT); blood investigation reports; any previous treatment records (chemotherapy or radiation history if applicable); and a completed TPA pre-authorisation request form. The hospital's insurance desk will assist in collecting and submitting all documents to your TPA. For PMJAY or MJPJAY patients, the respective government health scheme card and Aadhar card are required in addition. For CGHS or ECHS, the relevant service card and sanction letter from the competent authority may be needed.

Q175: Does CGHS / ECHS cover robotic cancer surgery?

Ans: Yes. The Central Government Health Scheme (CGHS) and the Ex-Servicemen Contributory Health Scheme (ECHS) cover robotic cancer surgery for beneficiaries at CGHS and ECHS-empanelled hospitals in Pune. These schemes operate on package-rate reimbursement — meaning a fixed CGHS-approved rate is applicable per procedure, regardless of the actual hospital cost. If the hospital's actual charges exceed the CGHS package rate, the difference must be borne by the patient (unless the treating hospital has agreed to accept CGHS rates in full). It is important to verify whether Sahyadri Manipal Hospital, Pune is currently on the CGHS and ECHS empanelled hospital list for your city zone, and whether the specific robotic surgical procedure required is included in the approved CGHS treatment package before planning admission.

Q176: Is robotic surgery covered under MJPJAY (Mahatma Jyotiba Phule Jan Arogya Yojana)?

Ans: Mahatma Jyotiba Phule Jan Arogya Yojana (MJPJAY) is the Maharashtra state government's health insurance scheme providing coverage for specified surgical procedures for eligible Maharashtra residents — including below-poverty-line families and identified occupational groups. Selected cancer surgery procedures — including specific oncological operations — are included in the MJPJAY package list at approved rates for empanelled hospitals in Maharashtra. Sahyadri Manipal Hospital, Pune participates in government health schemes. Eligibility for MJPJAY is verified by the hospital's MJPJAY desk using the beneficiary's yellow ration card, family photo ID, and cancer diagnosis documents. Patients who qualify for MJPJAY coverage can access robotic cancer surgery at empanelled hospitals at no cost for procedures within the approved package list. Contact the hospital's government scheme desk at +91 84118 08284 for specific guidance on your eligibility.

Q177: Are robotic consumables and 'technology fees' reimbursed by insurance?

Ans: The reimbursement of robotic consumables — the single-use instruments and accessories used during each robotic operation — by health insurance companies in India varies significantly by policy type, insurer, and policy vintage. Under IRDAI guidelines, robotic surgery cannot be blanket-excluded from health insurance coverage. However, individual policies may include sub-limits on consumable costs, cap the technology fee reimbursement at a fixed amount, or require a co-payment for robotic procedures. To avoid unexpected out-of-pocket expenditure, it is essential to obtain a written pre-authorisation from your TPA before surgery that explicitly states the approved coverage amount for the robotic procedure — including consumables. This written authorisation protects you from post-discharge claim disputes. The insurance desk at Sahyadri Manipal Hospital, Pune assists patients in obtaining clear written pre-authorisation for all robotic surgical procedures.

Q178: What is the total package cost (surgery + ICU + room + medicines) for robotic surgery in Pune?

Ans: An all-inclusive total episode cost — covering the robotic surgical procedure, anaesthesia, robotic consumables, ICU stay (if required), ward accommodation, nursing, routine medications, post-operative physiotherapy, and standard discharge medications — typically ranges from Rs 3.5 lakhs to Rs 10 lakhs for major robotic oncosurgery at Sahyadri Manipal Hospital, Pune, depending on the procedure, the type of ward accommodation selected, and the duration of recovery. The billing team at Sahyadri Manipal provides a detailed, itemised cost estimate before admission — broken down by component — allowing patients to understand the breakdown and to submit a complete estimate to their TPA for pre-authorisation. Patients are encouraged to request this itemised estimate at the time of their pre-operative surgical consultation.

Q179: Is EMI or finance option available for robotic cancer surgery in India?

Ans: Yes. Recognising that robotic cancer surgery represents a significant financial commitment for many families, Sahyadri Manipal Hospital, Pune offers medical finance options through registered healthcare finance partners — including Bajaj Finserv Health, CarePal Money, Arogya Finance, and other institutional healthcare lenders. These financing arrangements typically offer no-cost EMI (zero interest) for tenures of 6 to 12 months, or low-interest personal loan options for longer repayment periods. The application process is straightforward and can often be completed at the hospital on the day of admission. For patients with health insurance, the finance arrangement can cover the gap between the insurance reimbursement and the actual cost — such as co-payments, sub-limit shortfalls, or consumable charges not covered by the policy. Speak to the hospital's patient finance desk or call +91 84118 08284 for details.

Q180: How long is the hospital stay for robotic surgery and does insurance cover the full stay?

Ans: Hospital stay after robotic cancer surgery is typically 3 to 7 days for most major procedures — significantly shorter than the 7 to 14 days common after equivalent open operations. Health insurance policies in India cover the full in-hospital stay for medically necessary admissions. However, policies with per-day room rent limits — expressed as a percentage of the sum insured (e.g., 1 percent per day) — will restrict the eligible room category and may result in proportionate deductions from all hospital bills if a higher room category is chosen. To avoid post-discharge claim disputes, select a room category within your policy's daily room rent limit. Your hospital's billing team can advise on room categories that fall within your policy limits. Discharge is planned by the surgical team based on clinical criteria — not on insurance pressure — at Sahyadri Manipal Hospital, Pune.

Q181: What is the typical recovery time at home after robotic cancer surgery?

Ans: Home recovery after robotic cancer surgery is substantially faster than after open surgery, though it varies by procedure. General recovery timelines: after robotic prostatectomy — 2 to 3 weeks to light activity, 4 to 6 weeks to full recovery; after robotic colectomy or LAR — 2 to 4 weeks; after robotic hysterectomy — 4 to 6 weeks; after robotic Whipple — 4 to 6 weeks; after robotic lobectomy — 3 to 5 weeks; after robotic mastectomy — 2 to 4 weeks. These compare to 8 to 12 weeks for most of the equivalent open procedures. During home recovery, specific restrictions apply — including limitations on lifting, driving, swimming, and sexual activity — and these are communicated in writing at discharge. Follow-up appointments are scheduled at 1 to 2 weeks after discharge to review recovery and wound status.

Q182: Can I travel to Pune from another city for robotic cancer surgery?

Ans: Yes. Dr. Vinod Gore and the surgical oncology team at Sahyadri Manipal Hospital, Pune regularly treat patients from across Maharashtra — Nashik, Aurangabad, Solapur, Kolhapur, Nagpur, Satara — and from other states who travel to Pune for specialised robotic cancer surgery. For outstation patients, the initial consultation can be conducted via telemedicine — video call — with clinical records, imaging CDs, and biopsy reports reviewed online. After the virtual consultation, the surgical plan, approximate cost, pre-admission requirements, and optimal travel timing are communicated. Specific guidance on accommodation near the hospital, post-operative discharge planning, and virtual follow-up after return to the home city is provided. Contact the clinic at +91 84118 08284 or via the website to arrange an outstation consultation with Dr. Gore.

Q183: Do hospitals in Pune offer medical tourism packages for robotic cancer surgery?

Ans: Sahyadri Manipal Hospital, Pune — as part of the Manipal Health Enterprises group — offers comprehensive facilitated services for outstation patients and international medical visitors seeking robotic cancer surgery. These services include telemedicine consultations and second opinions, assistance with pre-admission documentation and insurance pre-authorisation, guidance on accommodation options near the hospital, airport transfer coordination, dietary support during admission including specific regional cuisine preferences, translation services where required, comprehensive discharge planning with take-home instructions in the patient's preferred language, and structured post-operative follow-up via video call after the patient returns home. For patients from overseas — including Indian diaspora patients seeking specialised cancer care — Dr. Vinod Gore's team provides detailed reports, operative notes, and histopathology summaries compatible with follow-up by treating oncologists in the patient's home country.

Q184: Does insurance cover pre-operative PET-CT and post-operative chemotherapy after robotic surgery?

Ans: Pre-operative PET-CT scans are covered by most health insurance policies when done as part of an inpatient admission or in a recognised day-care setting for the investigation of a confirmed or suspected malignancy — including pre-surgical cancer staging. If PET-CT is done on an outpatient basis before admission, coverage depends on whether your policy includes outpatient diagnostics. Post-operative chemotherapy — given as adjuvant treatment after cancer surgery — is typically covered as a separate claim under the 'cancer treatment' or 'day-care chemotherapy' provision of comprehensive health policies. Most cancer-specific health policies provide separate oncology benefit riders covering surgery, chemotherapy, and radiation. It is advisable to check with your TPA before starting chemotherapy to ensure pre-authorisation and to understand whether day-care chemotherapy cycles require fresh pre-authorisation each time.

Q185: Robotic surgery ka kharcha kitna hota hai India mein?

Ans: India mein robotic cancer surgery ka kharcha alag-alag procedure ke hisaab se alag hota hai. Approximate guide: robotic prostatectomy Rs 3.5 se 6.5 lakh; robotic colon ya rectal surgery Rs 3 se 6 lakh; robotic Whipple Rs 4.5 se 8 lakh; robotic lung surgery Rs 3.5 se 7 lakh; robotic mastectomy Rs 2.5 se 5 lakh; robotic hysterectomy Rs 2.5 se 5 lakh. Yeh estimate surgery, anaesthesia, robotic instruments, hospital stay, aur standard dawaiyan include karta hai. Zyaadatar health insurance is surgery ko cover karti hai — TPA se pehle written pre-authorisation lena zaroori hai. Sahyadri Manipal Hospital, Pune mein Ayushman Bharat, MJPJAY, CGHS, ECHS, aur cashless insurance facility available hai. Detailed estimate ke liye +91 84118 08284 pe call karein.

Q186: Who is the best robotic cancer surgeon in Pune?

Ans: Dr. Vinod T. Gore is among the most experienced and decorated robotic surgical oncologists in Pune. As Department Head, Surgical Oncology at Sahyadri Manipal Hospital since 2009, he has built and leads one of Pune's most comprehensive cancer surgery programmes. He holds the FARIS fellowship from the University of Edinburgh, leads a Robotic Surgery Centre of Excellence and FARIS training centre, and was awarded Best Robotic Oncosurgeon by Navbharat Times in 2024 and recognised as a Trailblazer Leader in Oncology by the Economic Times in 2025. With Tata Memorial Hospital training and nearly 30 years of surgical experience, he performs robotic cancer surgery across all major organ systems — GI, thoracic, breast, thyroid, uro-oncology, and gynaecological oncology.

Q187: What qualifications should a robotic cancer surgeon have in India?

Ans: A robotic cancer surgeon in India should ideally hold the following qualifications and credentials: an MBBS followed by MS in General Surgery from a recognised university; a superspecialty qualification in surgical oncology — either MCh Surgical Oncology, or a recognised fellowship such as from Tata Memorial Hospital or AIIMS; dedicated robotic surgery training documented by a recognised certification such as the FARIS fellowship from the University of Edinburgh or RSA India certification; and a verifiable case volume in robotic oncosurgery across the relevant organ systems. It is also important to verify that the surgeon's robotic programme is accredited or designated — for example, as a Centre of Excellence by the Robotic Surgeons Association. Academic contributions, teaching positions, and published outcomes data are additional markers of quality and commitment to excellence.

Q188: What is an MCh in Surgical Oncology and why does it matter?

Ans: MCh (Magister Chirurgiae) in Surgical Oncology is the highest postgraduate surgical qualification in India for the specialty of cancer surgery — a three-year, MCI-recognised superspecialty degree obtained after completing MS in General Surgery. It involves intensive training across all domains of solid-organ cancer surgery — head and neck, breast, thoracic, gastrointestinal, gynaecological, and uro-oncology — in addition to oncological principles including staging, multimodal treatment, and oncological outcomes. Not all surgeons who perform cancer operations in India hold an MCh in Surgical Oncology — some are general surgeons with limited specific cancer training. Choosing a surgeon with formal superspecialty surgical oncology training — whether MCh or an equivalent TMH-type fellowship — is important for ensuring the highest level of oncological expertise and judgement in your cancer care.

Q189: Is fellowship training in robotic surgery mandatory in India?

Ans: Fellowship training in robotic surgery is not legally mandatory for surgeons practising robotic procedures in India. However, it is strongly recommended by professional bodies including the Robotic Surgeons Association of India (RSA India) and the Indian Association of Surgical Oncology. The FARIS (Fellowship in Advanced Robotic and Innovative Surgery) programme from the University of Edinburgh is an internationally recognised structured robotic surgery fellowship that validates a surgeon's formal training, assessed competence, and commitment to robotic oncosurgery standards. The RSA India similarly offers Indian certification. A surgeon who has completed a formal robotic fellowship — and whose programme has been designated a Centre of Excellence — provides a measurable additional assurance of training quality and surgical standards compared to a self-taught robotic operator, particularly for complex cancer procedures.

Q190: How many robotic surgeries should a surgeon have performed to be considered experienced?

Ans: The concept of a surgical learning curve — the number of procedures required to achieve consistent technical proficiency and predictable outcomes — is well-studied in robotic surgery. For robotic prostatectomy, the most-studied procedure, a learning curve of 50 to 150 cases is commonly cited before consistent outcomes comparable to experienced centres are achieved. For complex procedures such as robotic Whipple surgery or robotic esophagectomy, learning curves extend to 30 to 50 cases at minimum in the hands of surgeons already experienced in open HPB surgery. A surgeon who performs multiple different robotic procedures — across GI, thoracic, breast, uro-oncology, and gynaecological oncology — and who leads a recognised Centre of Excellence with over 300 total robotic oncosurgeries, as at Sahyadri Manipal Hospital, Pune, has a broad and deep robotic experience base that patients can rely on.

Q191: What is the difference between a surgical oncologist and a general surgeon doing robotic surgery?

Ans: A surgical oncologist is a specialist who, in addition to general surgery training, has completed additional superspecialty training specifically in the surgical management of cancer — including oncological principles of resection, lymph node dissection, staging, reconstruction after cancer resection, and integration with chemotherapy and radiation therapy. A general surgeon — even one who is proficient in robotic technique — may not have this oncology-specific training. The implications are significant: for example, inadequate lymph node dissection during colorectal or gastric cancer surgery, inadequate margin assessment, suboptimal surgical staging, or failure to recognise and plan for reconstructive requirements may not be apparent to a general surgeon but would be second nature to a formally trained surgical oncologist like Dr. Vinod Gore. For cancer surgery, choosing a dedicated surgical oncologist rather than a general surgeon — regardless of robotic skill — is the most important decision.

Q192: Why should I choose a dedicated surgical oncologist over a general surgeon for cancer surgery?

Ans: The management of cancer demands a level of specialised knowledge and judgement that goes far beyond technical operative skill. A dedicated surgical oncologist understands the biology of different cancers, applies oncological resection principles — adequate margins, appropriate lymph node clearance, en-bloc resection — assesses the need for and plans reconstruction after cancer removal, coordinates with the medical oncologist and radiation oncologist for multimodal treatment planning, interprets complex pathology reports, and manages oncological complications and follow-up. A general surgeon, even one who is skilled in robotic technique for benign conditions, may not have this breadth of oncology-specific knowledge. For a patient with cancer — for whom the quality of the surgical resection directly determines long-term survival — choosing a surgical oncologist with dedicated training is the most important decision in the treatment journey.

Q193: What questions should I ask my robotic cancer surgeon before surgery?

Ans: Before agreeing to robotic cancer surgery, consider asking your surgeon the following questions to assess their expertise and suitability for your case: How many of this specific procedure have you performed robotically, and what is your annual volume? What is your personal conversion rate to open surgery for this procedure? What are your specific cancer control outcomes — R0 rate, lymph node yield, complication rate? Will you yourself perform the surgery, or will it be delegated to a trainee? What will happen if a complication occurs intraoperatively — do you have the backup of a senior team? How will my post-operative care be managed — do you have a dedicated nursing, physiotherapy, and dietetic team? What is the plan if I need adjuvant chemotherapy or radiation after surgery? Is your programme a recognised Centre of Excellence? These questions are entirely reasonable and any experienced surgeon should welcome them.

Q194: How do I verify a surgeon's robotic surgery credentials and case volume?

Ans: Verifying a surgeon's robotic credentials in India involves several steps. First, check the surgeon's Maharashtra Medical Council (MMC) registration number — which should be publicly verifiable on the MMC website — to confirm they hold a valid medical licence. Second, ask directly about their specific robotic surgery fellowship or certification — FARIS Edinburgh or RSA India — and request to see the certificate. Third, ask the surgeon or hospital for their annual and cumulative robotic case volumes by procedure type. Fourth, look for designation of their programme as a Centre of Excellence by the Robotic Surgeons Association — an institutional quality indicator. Fifth, check for published peer-reviewed papers or conference presentations, and for awards such as the Navbharat Times Best Robotic Oncosurgeon recognition awarded to Dr. Vinod Gore in 2024. Independent third-party verification through reputation, patient testimonials, and referring doctors provides an additional layer of assurance.

Q195: Does Sahyadri Manipal Hospital Pune have a dedicated robotic surgery programme?

Ans: Yes. Sahyadri Manipal Hospital, Pune has a dedicated and comprehensive robotic oncosurgery programme — formally designated as a Robotic Surgery Centre of Excellence by the Robotic Surgeons Association of India. The programme, led by Dr. Vinod Gore as Department Head Surgical Oncology, covers all major organ system robotic cancer surgeries: gastrointestinal and HPB, thoracic, breast and endocrine, uro-oncology, and gynaecological oncology. The programme is also a designated FARIS training centre — an accreditation that indicates it meets the training and outcome standards required by the Fellowship in Advanced Robotic and Innovative Surgery programme of the University of Edinburgh. The da Vinci robotic system at Sahyadri Manipal is equipped with the Firefly ICG fluorescence imaging system, enabling the full range of fluorescence-guided intraoperative applications as standard.

Q196: Who is Dr. Vinod Gore and what is his experience in robotic cancer surgery?

Ans: Dr. Vinod T. Gore is the Department Head, Surgical Oncology at Sahyadri Manipal Hospital, Pune — a position he has held since the department's inception in 2009. He holds MBBS and MS from the University of Pune (ranked 2nd in both examinations), completed a rigorous five-year surgical oncology residency at Tata Memorial Hospital, Mumbai — India's premier cancer centre — and holds the FARIS (Fellowship in Advanced Robotic and Innovative Surgery) from the University of Edinburgh. With nearly 30 years of surgical experience, Dr. Gore performs the full spectrum of complex robotic cancer surgery across all major organ systems. He was recognised as Best Robotic Oncosurgeon by Navbharat Times in 2024 and as a Trailblazer Leader in Oncology by the Economic Times in 2025. His robotic programme at Sahyadri Manipal is a Centre of Excellence and a FARIS training centre.

Q197: What types of robotic cancer surgeries does Dr. Vinod Gore perform at Sahyadri Manipal Hospital, Pune?

Ans: Dr. Vinod Gore performs a comprehensive range of robotic cancer surgery across all major organ systems at Sahyadri Manipal Hospital, Pune. His robotic practice includes: gastrointestinal and HPB oncosurgery — robotic Whipple, esophagectomy, gastrectomy, colectomy, low anterior resection, APR; thoracic oncosurgery — robotic lobectomy, segmentectomy, thymectomy; breast and endocrine surgery — robotic nipple-sparing mastectomy, thyroidectomy, adrenalectomy; uro-oncology — robotic radical prostatectomy, partial and radical nephrectomy, cystectomy, RPLND, VEIL for penile cancer; gynaecological oncology — robotic radical hysterectomy, TLH-BSO with staging lymphadenectomy; and ICG fluorescence-guided surgery — sentinel node mapping, anastomotic perfusion assessment, margin assessment. This full-spectrum robotic oncosurgery programme is supported by a multidisciplinary clinical team and NABH-accredited facilities at Sahyadri Manipal Hospital, Pune.

Q198: How can I book an appointment with the best robotic surgical oncologist in Pune?

Ans: To book a consultation with Dr. Vinod Gore — Department Head Surgical Oncology, Sahyadri Manipal Hospital, Pune, and Navbharat Times Best Robotic Oncosurgeon 2024 — you have several options. In person or telephone: call Silver Leaf Clinic, 511 City Centre, Solapur Road, Opposite Vaibhav Theatre, Hadapsar, Pune 411028 at +91 84118 08284 to book an OPD appointment at Silver Leaf Clinic or at Sahyadri Manipal Hospital. Online: visit bestroboticsurgeonpune.in to use the appointment request form. Telemedicine: for outstation patients who cannot travel initially, a teleconsultation can be arranged — please bring all available medical records, imaging CDs or DICOM files, biopsy reports, and prior treatment summaries to the online consultation. Email: vinodgore@gmail.com. For urgent cancer-related consultations, the team makes every effort to accommodate priority appointments.

Q199: Does Dr. Vinod Gore offer a second opinion for robotic cancer surgery online?

Ans: Yes. Dr. Vinod Gore offers formal teleconsultation and second opinion services for patients and their families who are unable to attend in person at Silver Leaf Clinic or Sahyadri Manipal Hospital, Pune. A second opinion is particularly valuable when a cancer diagnosis is complex, when multiple treatment options have been presented, when a previous surgeon has recommended open surgery but the patient wishes to explore whether a robotic approach is appropriate, or when the patient wishes an independent review of the proposed treatment plan. For the teleconsultation, please have the following available: biopsy or histopathology report, CT scan or MRI imaging (DICOM CD or shared link), PET-CT report if done, blood investigation reports, previous treatment records, and a list of current medications. Appointments can be booked at +91 84118 08284 or via bestroboticsurgeonpune.in.

Q200: Why is Sahyadri Manipal Hospital Pune a leading centre for robotic cancer surgery in Maharashtra?

Ans: Sahyadri Manipal Hospital, Pune occupies a unique position in Maharashtra's cancer surgery landscape for several converging reasons. It is a Robotic Surgery Centre of Excellence — designated by the Robotic Surgeons Association — and a FARIS training centre — meaning it meets the international training and outcome standards of the University of Edinburgh's robotic surgery fellowship programme. It is led by Dr. Vinod Gore, a Tata Memorial Hospital-trained surgical oncologist with nearly 30 years of experience, FARIS Edinburgh qualification, and recognition as Best Robotic Oncosurgeon by Navbharat Times 2024 and Trailblazer Leader in Oncology by the Economic Times 2025. The programme covers all major organ systems, uses ICG fluorescence-guided surgery routinely, and operates within a NABH-accredited hospital with full oncology, pathology, radiology, and anaesthesia support — making it one of the most comprehensively equipped robotic cancer surgery centres in Maharashtra.